Starpharma Annual Report 2006



STARPHARMA HOLDINGS LIMITED ABN 20 078 532 180

## Contents

Review of Operations	02
Directors' Report	19
Corporate Governance Statement	36
Financial Report	41
Shareholder Information	80
Patent Report	82
Corporate Directory	85



2	005–06 Highlights
>>>	HIV Funded: \$26m National Institutes of Health (NIH) funds VivaGel <sup>™</sup> HIV Development: \$26m non-dilutive funding
>>>	Genital Herpes Funded
>>	HIV Fast-tracked US regulator, FDA designates VivaGel <sup>™</sup> a fast track product.
•••	Herpes IND Cleared FDA clears VivaGel <sup>™</sup> genital herpes IND
	Contraceptive Activity Identified VivaGel <sup>™</sup> shown to be a potent contraceptive in animals Future Revenues Improved
>>	Royalty for stock swap: future revenues enhanced \$15m Funds Raised
>>	\$15m raised in institutional and SPP capital raising Patent Estate Expanded
<b>&gt;&gt;</b>	Substantial program of patent filing completed Priostar <sup>™</sup> Rolled Out Investee company DNT rolls out Priostar <sup>™</sup> industrial dendrimer platform
>>	ADRS: Near 10% US uptake of ADRs nears 10% of SPL capital

Starpharma uses dendrimer nanotechnology to discover, develop and commercialise pharmaceuticals for serious human illness.



"The environment for VivaGel<sup>™</sup> has greatly improved from a funding, clinical, regulatory and global awareness perspective"

# **CEO and Chairman's Report**





Dear Shareholder,

It is with pleasure that we present the Starpharma Annual Report 2005–2006.

It has been a year in which the environment for our lead product VivaGel<sup>™</sup> (SPL7013 Gel) has greatly improved from a funding, clinical, regulatory and global awareness perspective. We have a product that is scientifically and commercially viable and gaining significant international interest, especially in the USA.

In October 2005, Starpharma secured A\$26m of non-dilutive funding from the US-based National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of VivaGel<sup>™</sup> against HIV. This award provides many of the benefits of a commercial licensing deal – security of development funding, validation of product concept, access to clinical expertise and influence – but without the loss of product ownership that is the usual cost of such transactions.

VivaGel<sup>™</sup> continues to make good clinical progress and we are now preparing for new clinical trials to begin for both HIV and genital herpes indications. These trials have already commenced in Australia and will be extended shortly into the USA and Kenya. Starpharma believes that VivaGel<sup>™</sup> is the first microbicide to have both NIH funding and a Food and Drug Administration (FDA) IND application for the genital herpes indication, a disease affecting 45 million Americans today.

VivaGel<sup>™</sup>'s attraction to end users and to potential licensees was further enhanced by the discovery that its active ingredient is a potent contraceptive in rabbits. The proposition that VivaGel<sup>™</sup> could protect against sexually transmitted infections and unplanned pregnancy could result it becoming a very attractive product for sexually active women globally.

Significantly, the demand for the accelerated development of microbicides has gained momentum with world leaders such as former US president Bill Clinton and Microsoft founder Bill Gates further emphasizing the importance of prevention strategies such as microbicides in the fight against HIV/AIDS.

Beyond VivaGel<sup>™</sup> Starpharma's long term growth will come from our own discovery pipeline and from investee company Dendritic Nanotechnologies Inc (DNT). Starpharma's pipeline holds great promise in areas as diverse as cancer, ophthalmology, infectious diseases and diagnostics. Additionally, through DNT we also benefit from an extensive portfolio of dendrimer products for industrial and other life science applications. Already earning revenues, the commercial prospects for DNT's technology have been substantially boosted this year by the launch of Priostar™ for a range of applications. We continue to view our equity stake in DNT as a highly valuable and complementary asset in Starpharma's portfolio.

The combination of successful fundraising activity in November 2005 – where Starpharma raised \$15million through a share placement and share purchase plan – together with the funding allocated from the NIH for VivaGel<sup>™</sup>, means that Starpharma has a solid financial basis for the commercialisation of VivaGel<sup>™</sup> and the development of additional applications of dendrimers.

We strengthened our intellectual property position by acquiring the outright ownership of technology from the Biomolecular Research Institute (BRI). As a result Starpharma will not need to pay any future royalties to the BRI and this is anticipated to result in much greater value for shareholders.

US interest in Starpharma continues to grow with an extremely successful American Depositary Receipts program that now represents almost 10% of the company's equity – more than double that reported in last year's annual review.

Finally, on behalf of the board we would like to thank staff and management for their contribution to an excellent year. In particular we thank Dr John Raff, who retired as CEO in July 2006 for his enormous contribution to Starpharma's success: in many ways the company as it stands today is his creation. We consider it a privilege to build upon this foundation, and to turn the investment that has been made in the company and its technology into a valuable return for shareholders. We also look forward to John's continued support on the Starpharma Board.

Peter T Bartels AO Chairman


Jackie Fairley B.Sc., B.V.Sc. (Hons), MBA. Chief Executive Officer




"Australian scientists are at the vanguard of microbicide development."

Sir Gus Nossal, December 2005


## **Financial Snapshot**





# **About Starpharma**

Below Starpharma's Dendrimer particles are a few nanometres in size. This makes them very applicable to the modification of biological interactions, for example those of the surface proteins of viruses. The virus shown here is approximately 100nm in size.



Starpharma is an Australian-based bio-nanotechnology company.

Starpharma's objective is to discover, develop and commercialise profitable products based on dendrimers. Dendrimers are man-made chemical particles in the nanometre size range – that is, around one billionth of a metre. They have precisely-defined surface features and wide range of applications from healthcare and personal care to manufacturing and electronics.

Much of Starpharma's value comes from its opportunities for substantial revenues from three key areas:

#### VivaGel<sup>™</sup> (SPL7013 Gel):

The most advanced product in Starpharma's pipeline. It is being developed as a vaginal microbicide intended to prevent the transmission of the sexually transmitted infections genital herpes and HIV. This is a mass-market application in both developed and developing countries.

# Other Medical and Life Science Applications:

Within its own discovery pipeline, Starpharma is pursuing promising leads in fields such as cancer, ophthalmology and targeted diagnostics. Its investee companies, including Dendritic Nanotechnologies, Inc (DNT), also provide additional avenues of commercialisation, for example, in drug delivery, transfection reagents and contrast agents. Contrast agents improve the ability of diagnostic imaging tools to discern features in the body, improving diagnoses and patient outcomes. It is expected that returns will be made in these areas primarily by licensing rights to successful innovations to third parties.

#### Industrial Applications of Dendrimers:

This is an opportunity being exploited through our investee company DNT. The market for these kinds of specialty chemicals tends to be larger volume, and hence also represents a very substantial commercial opportunity. Dendrimers may have applications in areas such as electronics, oil and plastics industries, just to name a few.

Together Starpharma and DNT hold a strong Intellectual Property (IP) position with regard to dendrimers and their applications.

#### Stock Exchange Listing

Starpharma is listed on the Australian Stock Exchange (ASX:SPL) and its American Depository Receipts trade under the symbol SPHRY.




"If I had a magic bullet to accelerate something it would be the microbicide."

Bill Gates, July 2006



# VivaGel™ The product

**Below** HIV virus (purple) including gp–120 protein (yellow). Dendrimers are believed to bind to gp–120, preventing transmission of the HIV virus.



Starpharma's aim is for women to be able to use VivaGel™ (SPL7013 Gel) as a "Vaginal Microbicide" to protect themselves from sexually transmitted infections (STIs), such as genital herpes and HIV. There are currently no vaginal microbicides available to women.

## A global medical problem

The spread of genital herpes and AIDS (caused by HSV-2 and HIV viruses respectively) continues apace, despite education campaigns designed to promote safe-sex messages and practices. Around the world, researchers in academia and industry have been attempting to develop vaccines for these diseases, so far with limited or no success.

#### **Genital Herpes**

Approximately 45 million Americans are infected with HSV-2. Genital herpes is a recurrent, lifelong viral infection and one of the most prevalent sexually transmitted infections, estimated to infect between 15% and 25% of male and female adults, respectively, in developed countries. This figure is expected to rise to almost 40% for males and 50% for females by 2025, unless effective preventive measures can reverse the trend. Additionally, HSV-2 infection can make people more susceptible to infection by HIV, making its prevention even more important.

#### HIV

HIV infection is a major health burden in both the Western world and developing countries. Approximately 40 million people worldwide are infected with HIV. In the US, AIDS is the number one cause of death among African-American women aged 25 to 34.

The United Nations has estimated that as many as 90 million people in Africa alone may be infected with HIV over the next 20 years if the spread cannot be stopped. AIDS is difficult and expensive to treat and there is no cure.

#### **Prevention is better than cure**

A new approach is required to control the spread of HIV/AIDS and genital herpes. With no available cure and limited success of existing strategies for prevention of HIV and HSV-2 infection, a vaginal microbicide is recognised as a key element in the fight to slow the spread of genital herpes and AIDS.

Starpharma's goal is to show that VivaGeI<sup>™</sup> is a safe and effective vaginal microbicide that women could use to protect themselves from these infections, and to address the problem at its source. Much work is already done: in very stringent animal models for these diseases the gel has proven very effective. It has also been successfully tested for safety in animals and in an initial human trial. Starpharma and expert partners are now working on a program to demonstrate safety in larger populations, and to determine whether VivaGel<sup>™</sup> is in fact as effective in women as animal studies have indicated. Another important feature of microbicides such as VivaGel<sup>™</sup>, if approved, is that it would be women who would most directly manage their use (unlike condoms), giving them more power to protect themselves from Sexually Transmitted Infections ("STIs").

VivaGel<sup>™</sup> would be used with a single-use, pre-filled vaginal applicator. The economics of the product – active ingredient, formulation and applicator – are seen to be well matched to a mass market application.

VivaGel<sup>™</sup> has also been shown to be a contraceptive in rabbits, and compatible with condoms in laboratory tests.

The active ingredient of VivaGel<sup>™</sup> is a dendrimer. Dendrimers are carefully-assembled tiny particles with many potential applications in medicine and industry.

The surface of the active dendrimer in VivaGel<sup>™</sup> is covered with regions that are thought to bind to the HIV or HSV-2 viruses. Scientists believe that the microbicidal activity already proven in animals arises because the viruses cannot enter cells when the dendrimer is attached, and so cannot cause infection.

# 

# "You shouldn't wait for a vaccine"

Eric Goemaere, Médecins Sans Frontières, July 2006 on the future of HIV medicine.



# VivaGel™ Progress to market

**Below** A representation of VivaGeI<sup>™</sup>'s active ingredient SPL7013. Shown here in red and yellow are active groups that are believed to bind to HIV and HSV-2 viruses, rendering them inactive.



The VivaGel<sup>™</sup> (SPL7013 Gel) development plan is conducted with the aim of approval by the US-based Food and Drug Administration and other major regulatory authorities around the world. Starpharma works closely with these authorities to ensure that their needs are properly met in the data that is compiled.

The program for VivaGel<sup>™</sup>'s clinical development includes trials in both developing and developed countries: USA, Kenya, Thailand and Australia. The data from all these locations will be drawn upon to support the case for its approval for marketing.


The map (opposite) illustrates the global nature of VivaGel<sup>™</sup> related activities.

Beyond the safety trial in men and the genital herpes safety trial in women described previously, a number of further clinical trials are proposed to start in the coming year, including a safety trial in HIV positive women conducted through the Thai Red Cross Aids Research Centre in Bangkok.

## VivaGel<sup>™</sup> development timeline

Previously	Extensive safety and efficacy trials in animals. Phase I randomized clinical trial involving 36 healthy female volunteers showed VivaGeI™ to be safe and well tolerated over a range of doses of active component, when applied vaginally once daily for seven consecutive days.
October 2005	Starpharma received an award of A\$26 million toward the development of VivaGel <sup>™</sup> from the National Institute of Allergy and Infectious Diseases of the US NIH. This is one of the largest awards ever made in Australia by the NIAID. The NIH is the primary Federal agency in the US for conducting and supporting medical research, comprising 27 institutes and centres.
January 2006	VivaGel <sup>™</sup> was designated as a Fast Track product by the US FDA for use against HIV, meaning that the New Drug Application to the FDA can be reviewed within a shorter time period (as short as 6 months compared to a more usual 13).
April 2006	Starpharma signed a second agreement with the NIAID for clinical trial funding of VivaGel™ for genital herpes.
*July 2006	In a recent independent study undertaken at Johns Hopkins University in the USA, the active ingredient in VivaGel <sup>™</sup> , SPL7013, exhibited a potent contraceptive effect in animals. The proposition that VivaGel <sup>™</sup> could provide protection from STIs and also contraceptive protection may make the product particularly attractive to women.
*July 2006	The FDA allowed an IND to conduct a clinical trial for genital herpes. The trial will be run concurrently in Kenya (Kisumu), and the USA (San Francisco), and is expected to commence shortly.
*August 2006	Commencement of a safety trial in men for VivaGel™ following successful review by local ethics committees, the FDA and the NIH.

\* Post June 30 2006 events.



Creating and using structures, devices and systems that have novel properties and functions because of their small and/or intermediate size.

Ability to control or manipulate on the atomic scale."

US National Nanotechnology Initiative definition of nanotechnology.



# **Dendrimer Nanotechnology**

#### Potential applications of Dendrimers

#### Personal and Household

- Cleaners and lotions Cosmetics
- Pigments and Dyes
- UV absorber Sacrificial Carrier
- (Nutritionals)
- Surfactancy Improved binders

## Medical and Health

- Pharmaceuticals Diagnostic imaging Diagnostic sensing Drug delivery Drug discovery Remote and in-vivo devices Transfection
- Tissue engineering Controlled release

Chemical sensors and biosensors Environmental sensing Remediation Clean water (ion exchange) Clean air (super absorbers)

Environment

## Improved catalysts

## Energy and Electronics


Fuel cells (membranes. catalysts) Energy storage (hydrogen) Solid state lighting Thermal management for devices LEDs, displays, Electronic inks Interlayer dielectric, Photoresistors Molecular Electronics Telecom devices (waveguides)

## Food and Agriculture · Targeted, non-toxic

biodegradable pesticides, herbicides Time-release fertilizers and pesticides Packaging (microbe resistant plastics) Freshness, Contamination, and/or tampering sensors Delivery of genes and drugs to plants and animals

#### Chemicals and Manufacturing

High performance Chemical Catalysis Chemical Separations Filtration Systems Petrochemical Processing (nanocatalysts) Toxic leak sensors Highly selective control sensors



Nanotechnology can be defined as the manipulation of matter at the atomic level. It can also be defined with reference to a size: nano-products or their components are in the 1-100 nanometre range (i.e. from 1 billionth of a metre, to one hundred times this size.)

Dendrimers are nanoscale molecular building blocks with precisely defined properties. They have applications in fields as diverse as energy, electronics, food, agriculture, fine chemicals, manufacturing, environmental engineering, medicine, health, as well as personal and household applications.

Many of Starpharma's dendrimers are constructed using one of the body's own building blocks, a constituent of protein called lysine. Starpharma constructs dendrimers by taking a small core molecule, then repeatedly adding the lysine branching unit until a spherical nanoparticle is created. The well-defined method of construction means each nanoparticle is identical: it is this fundamental manipulation of atoms into a nanoscale structure that gives dendrimers their versatility, reproducibility and power.

Starpharma has focused its dendrimer research efforts to capture value from applications of nanoparticles in pharmaceutical and bioscience markets. Other applications are exploited through its investee company Dendritic Nanotechnologies Inc (DNT).

#### Illustrative areas of Starpharma's dendrimer patent protection

## Intellectual Property (IP)

During the year the Company significantly enhanced its patent portfolio as a result of filing a further twelve patent applications. These applications have arisen as a result of the Company's further substantial development of its dendrimer technologies in high value applications. In additon, the Company's patent portfolio has been enhanced by the granting of various patents in a range of jurisdictions. As at the date of this report the Company owns 19 patent families consisting of 36 granted patents and 60 pending applications.

This augments the 196 dendrimer patents transferred to DNT by the Dow Chemical Company in 2005, from which Starpharma has all rights for polyvalent pharmaceutical applications.

VivaGel™	Dendrimers as	Dendrimers as	Other Life Science
	Drug Modifiers	Drugs	Applications
<ul> <li>Composition of matter</li> <li>STI Prevention HIV HSV-2 Other STIs</li> <li>Contraception</li> <li>Condom coatings</li> </ul>	<ul> <li>Drug Delivery</li> <li>ADME<sup>1</sup> engineering and Pharmacokinetic modification</li> <li>Solubility enhancement</li> <li>GPCRs</li> </ul>	<ul> <li>Angiogenesis inhibitors</li> <li>Age-related</li> <li>Macular</li> <li>Degeneration</li> <li>Oncology</li> <li>Inflammation</li> <li>Other</li> <li>Anti-toxins</li> </ul>	<ul> <li>The creation of macromolecules with highly defined, structural surfaces</li> <li>Targeted diagnostics</li> </ul>

<sup>1</sup> ADME: Adsorption, Distribution, Metabolism and Excretion

Refer to pages 82 to 84 for a full list of Starpharma Patents


THA BERAD

"Dendrimers can be prepared with the precision of small organic molecules, yet they behave like macromolecules"

B.Helms and E.W. Meijer, *Science,* August 2006

# **Growth Strategy**

Below Artist's impression of the dendrimer SPL7013 binding to HIV surface proteins to inactivate them. Without active surface proteins HIV cannot infect human cells.



#### **Platforms and Products**

Starpharma has created a number of nanotechnology "platforms" that meet important challenges in today's pharmaceutical and life-science industries. As well as making them available to partners, Starpharma applies these platforms within its own laboratories to address specific human diseases. VivaGeI<sup>™</sup> is the most advanced such product. Both the compounds arising from this pipeline and also the underlying platforms can yield revenues from licensing.

#### **Nanotechnology Platforms**

Dendrimers are well-defined molecules with many surface attachment locations. They can be "adaptors" connecting different elements together into a multifunctional molecule. This capability is of value in many pharmaceutical and life-science applications but historically has been difficult to achieve reproducibly. Starpharma's technology provides this capability, and it is being developed as four principal platforms.

#### Drug Delivery

Many drugs would be enhanced if more accurately directed to their target tissues. Efficacy could be increased and toxicity reduced. Dendrimers may be a good choice for drug delivery: they may be used to transport drugs through the body, to be released at an appropriate site or time. Starpharma has demonstrated that both small molecule drugs and "biologicals" can be attached to dendrimers. Biologicals peptides, proteins and other compounds derived from biological sources such as antibodies - are of particular significance because of growing interest in their use, particularly in chronic diseases such as Rheumatoid Arthritis and Cancer.

#### ADME Engineering<sup>™</sup>

The properties of a drug can be modified by attaching it to a dendrimer more permanently. Starpharma refers to this technique as ADME Engineering<sup>™</sup> (ADME: "Absorption, Distribution, Metabolism, Excretion"). For example, the rate at which the body expels a drug can be minimised allowing reduced dosing frequency. Alternatively a drug can be excluded from certain tissues or organs. This technology has been demonstrated in a number of applications by Starpharma and the company is now investigating opportunities to apply ADME Engineering<sup>™</sup> within our partners' development programmes.

#### **Targeted Diagnostics**

Diagnostic imaging tools like MRI and PET scans allow today's clinicians to deliver better patient outcomes through earlier intervention and more tailored therapies. The success of this approach is governed by the quality of the images from the scans. By introducing "contrast agents" into the body – scan-visible compounds which target defined tissues - the scans can be enhanced. Starpharma's Targeted Diagnostics platform offers the opportunity to connect "targeting" molecules to multiple "signaling" molecules to improve scan images and quality of care.

#### Polyvalency

Another beneficial property of dendrimers is "polyvalency". By arranging multiple copies of a binding group on the surface of the dendrimer, multiple simultaneous targetbinding events can be achieved (rather like Velcro™) yielding potency far beyond that of a single binding group. VivaGel™'s active ingredient SPL7013 exemplifies this approach: its surface groups have strong anti-viral properties when multiply-presented on SPL7013, but not as free molecules.

#### **Biotechnology Product Applications**

Starpharma's "in-house" applications of these platforms include:

# Cancer Therapeutics – (based on Drug Delivery and ADME Engineering<sup>™</sup> platforms)

Starpharma is using dendrimers to improve the characteristics of existing anticancer drugs. Attaching established, marketed oncology drugs to dendrimers may make these drugs easier to administer whilst being safer and more effective for the patient.

# Ophthalmic Diseases – (based on Polyvalency platform)

Starpharma has a range of dendrimer molecules under development that have been shown to reduce angiogenesis in *in vivo* assays. One indication for this mode of action is in ophthalmic disorders such as Age-related Macular Degeneration (AMD) – a disease with an estimated 15 million sufferers in the U.S. alone – and Starpharma will work with specialist partners to assist in the development of this and other ophthalmic applications of dendrimers.

#### Anti-virals – (based on Polyvalency platform)

Starpharma's dendrimers have already demonstrated convincing *in vivo* antiviral activity in VivaGel<sup>™</sup>. Starpharma's dendrimer library has also shown *in vitro* or *in vivo* activity against many other viruses in early studies beyond HIV and HSV-2, including in RSV, influenza, Hepatitis B, and other widespread, lethal viral disorders. Starpharma will work with partners to advance these opportunities into preclinical and clinical studies.

# Cardiovascular Diagnostics – (based on Targeted Diagnostic platform)

Starpharma is developing a dendrimer based contrast agent for targeted cardiovascular diagnostics in association with a specialist organisation in the area of cardiac health.



"The majority of dendrimer IP is pooled in one company, Dendritic Nanotechnologies (DNT)"

Lux Research, 2006

\*\* \*\*

11

# **Dendritic Nanotechnologies Inc**



Below Artists impression of a "polyvalent" dendrimer forming multiple Velcro-like interactions with proteins in a cell membrane.



Dendritic Nanotechnologies Inc (DNT) is a US based company founded by Starpharma and dendrimer pioneer Don Tomalia, to commercialise applications of dendrimers in pharmaceutical as well as industrial settings. In 2005 the Dow Chemical Company became a major share holder of DNT, assigning its entire dendrimer IP portfolio to DNT in the process.

DNT also has particular value to Starpharma providing a US base with important commercial and financial linkages.

Starpharma identifies four key classes of assets associated with DNT:

## A dominance of the Intellectual Property landscape with over 100 dendrimer nanotechnology patents.

The portfolio was initially established by Dr Donald Tomalia and the Dow Chemical Company and was assigned by Dow in its entirety to DNT in exchange for a share of the company's equity. As well as sharing in the profits that will accrue from this dominant position, Starpharma has exclusive right to existing and future polyvalent

pharmaceutical applications of dendrimers.

#### Established revenue streams

DNT receives revenue each year both through sales of dendrimer material, and through existing licensing agreements. As well as providing a contribution to the company's bottom line, this revenue stream supports the view that dendrimers are already a viable commercial proposition. This is a major differentiator compared to many other nanotechnology companies today.

## Relationships with key industry corporations

DNT has a range of valuable commercial, research and development relationships, including with:

- Pfizer,
- Sigma-Aldrich,
- Dharmacon,
- Dade Behring,
- · Lumera, and
- Qiagen

DNT also has established relationships with other organization such as the NIH, the National Cancer Institute, the US Army and Caltech.

#### Priostar™

Priostar<sup>™</sup> is a particularly robust, low-cost, versatile class of dendrimers very well suited to large scale, industrial applications. DNT is currently in commercial discussions with a number of potential partners to apply this technology in the areas of plastics, high performance oil, and household products.



Extract from DNT's product catalogue



Left to right Guy Krippner Tom McCarthy Tim Grogan Paul Barrett Jeremy Paull Jackie Fairley Nigel Baade Ben Rogers

Headed by recently appointed CEO, Dr Jackie Fairley, Starpharma's management team provides the expertise and experience necessary to fulfill its commitment to create value, through the development and commercialisation of new pharmaceutical products based on dendrimers.

## Jackie Fairley Chief Executive Officer

B.Sc., B.V.Sc. (Hons), MBA Jackie has over 15 years' experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Mayne Pharma). Before joining Starpharma in 2005 she was Chief Executive Officer of Cerylid Biosciences. She also spent 5 years as a Vice President for Faulding's injectable division and 5 years with CSL in various executive roles. Jackie holds first class honours degrees in Science (pharmacology/ pathology) and Veterinary Science, and has an MBA from the Melbourne Business School where she was the recipient of the Clemenger Medal.

#### Nigel Baade Financial Controller

B.Com, CPA, Grad. Dip. Arts (Development) Nigel Baade is a CPA qualified accountant with experience in the pharmaceutical and biotechnology industries. His previous roles have included Finance Manager of Cerylid Biosciences; and Manager Accounting, International Business Development for Faulding (now Mayne Pharma). Prior to joining Starpharma in January 2006, Nigel held a commercial planning role with multinational, Hagemeyer.

## Paul Barrett Vice President Business Development B.Sc. (Hons), Ph.D.

Paul has 6 years' experience in marketing and business development gained in both start-up and multinational technology companies in the UK. His employers have included Nortel Networks, Smiths Industries Aerospace and Bookham Technology. His doctoral and post-doctoral studies were conducted at Heriot-Watt University and the University of Oxford, UK. Paul's technical publications range from molecular biology and bioinformatics to photonics and telecommunications.







# **Management Team**

## Tim Grogan Vice President Commercial Development and Licensing *LLB*, *B.Sc.*

Tim has had extensive experience in business and technology management including positions at Monsanto Australia Ltd, Freehill Hollingdale & Page and as a Director of Ag-Seed Research Pty Ltd. Tim was a driving force behind Starpharma's venture with Donald Tomalia, Ph.D. which resulted in the establishment of DNT. Tim completed his law and science degrees at Melbourne University and was admitted as a Barrister and Solicitor of the Supreme Court of Victoria and High Court in 1991.

Guy Krippner Head of Chemistry BSc (Hons), Ph.D Prior to joining Starpharma in 2002 Guy headed Prana's chemistry program targeting Alzheimer's disease. Previously he was a Senior Research Scientist at Biota Holdings Ltd developing antiviral therapeutics and diagnostics. Guy's doctoral and post doctoral research was conducted at the University of Adelaide, South Australia and the University of Oxford, UK.

#### Tom McCarthy Vice President Drug Development B.Sc. (Hons), Ph.D.

Tom joined Starpharma in 2001. He is Principal Investigator of Starpharma's NIH grant "Development of Dendrimer and Combination Microbicides, and of a US\$20.3M NIH contract to develop VivaGeI'". Prior to Starpharma at the Biomolecular Research Institute Tom managed the discovery chemistry aspects of in-house and collaborative projects, including with Prana Biotechnology Ltd and the Austin Research Institute. Tom's early research was conducted at the University of Oxford, UK and at CSIRO, Australia.

#### Jeremy Paull Vice President Regulatory

and Clinical Affairs B.Sc. (Hons), Ph.D. Jeremy has several years' experience in regulatory affairs and quality assurance, gained at Starpharma and previously at another Australian biotechnology company, Norwood Abbey. At Starpharma, Jeremy has been instrumental in the VivaGel<sup>™</sup> development program since its inception, and was responsible for the implementation of the first clinical trials conducted by Starpharma under the IND. At Norwood Abbey he worked on the development of a medical device which was approved to improve transdermal drug delivery. Jeremy received a Ph.D. in Pharmacology from Monash University.

## Ben Rogers Company Secretary and Chief Financial Officer

Ben Rogers has extensive experience in finance and human resources management with the CSIRO research laboratories in Victoria, South Australia, and Western Australia. He also operated his own consulting business providing services to Co-operative Research Centres and CSIRO Divisions. Ben joined Starpharma on commencement of operations in April 1997 and was appointed to the position of Company Secretary in February 1998.



# **Directors' report**

Your directors have pleasure in presenting this report on the consolidated entity consisting of Starpharma Holdings Limited and the entities it controlled at the end of, or during, the year ended 30 June 2006.

## Directors

The following persons were directors of Starpharma Holdings Limited ("the Company") during the whole of the financial year and up to the date of this report: P T Bartels (Chairman) P M Colman R Dobinson L Gorr P J Jenkins J W Raff

J K Fairley was appointed a director on 1 July 2006 and continues in office at the date of this report.

## **Principal Activities**

The principal activities of the Company consist of investment in, and management and funding of dendrimer based research, development and commercialisation. Activities within the Company are directed towards the development of precisely defined nano-scale materials for use in pharmaceutical applications, with a particular focus on the development of topical vaginal microbicides for the prevention of HIV and other sexually transmitted diseases. These activities are managed by the wholly owned subsidiary Starpharma Pty Ltd.

## Dividends

No dividend has been paid or declared during or since the end of the financial year.

## **Review of Operations**

Information on the operations and financial position of the Group and its business strategies and prospects is set out in the review of the operations and activities on pages 2 to 18 of this annual report.

## **Operating Loss**

For the year ended 30 June 2006 the consolidated entity incurred an operating loss after income tax of \$7,522,789 (June 2005: \$7,747,791).

## Significant changes in the state of affairs

In the opinion of the directors there were no significant changes in the state of affairs of the consolidated entity that occurred during the financial year under review not otherwise disclosed in this report or in the financial statements.

## Matters subsequent to the end of the financial year

On 1 July 2006, Dr J W Raff retired as Chief Executive Officer (CEO) of the Company and the Chief Operating Officer, Dr J K Fairley, was appointed to the position of CEO. Dr Fairley was also appointed as a director. Dr Raff remained a director of the Company and accepted the role of Deputy Chairman of the Board.

No further matters or circumstances have arisen since 30 June 2006 that have significantly affected, or may significantly affect:

- 1. the consolidated entity's operations in future financial years, or
- 2. the results of the operations in future financial years, or
- 3. the consolidated entity's state of affairs in future financial years.

## Likely developments and expected results of operations

In the opinion of the directors, the consolidated entity will continue its activities as described. Further information on likely developments in the operations of the consolidated entity and the expected results of operations have not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the consolidated entity.

## **Regulatory Environment**

There were no significant changes in laws or regulations during 2005/06 or since the end of the year affecting the business activities of the consolidated entity, and the directors are not aware of any such changes in the pipeline.

## Environmental regulation

The Company recognises the importance of environmental issues and is committed to the highest levels of performance. There are adequate systems in place to ensure compliance with Commonwealth and State environmental regulations and the Directors are not aware of any breach of applicable environmental regulations by the consolidated entity.

## Legal

At the date of the Directors' Report there are no significant legal issues.

## Health and Safety

The Board, CEO and senior management team of Starpharma are committed to providing and maintaining a safe and healthy working environment for the Company's employees and anyone entering its premises or with connection to the Company's business operations. The Company has adopted an Occupational Health and Safety (OH&S) Policy and has established an OH&S Committee as part of its overall approach to workplace safety. Further details of the Company's policy and practices are set out in the corporate governance statement on page 39 of the annual report.

## Information on Directors

## **Peter T Bartels,** *AO* Chairman – Non-executive, Age 65.

## Experience and expertise

Independent non-executive director and Chairman for three years. Previously CEO and Managing Director of Coles Myer Ltd and before that CEO and Managing Director of Fosters Brewing Company Ltd. Has also had broad-based experience in the pharmaceutical industry in previous roles with DHA Pharmaceuticals and Abbott Laboratories. Chairman of the Australian Sports Commission and the Australian Institute of Sport. Past chairman of the Commonwealth Heads of Government Committee for Sport and the Women's and Children's Health Service. Other current directorships None.

Former directorships in last 3 years None.

Special Responsibilities Chairman of the Board. Member of remuneration & nomination committee.

Interests in shares and options 109,804 ordinary shares in Starpharma Holdings Limited

## John W Raff Dip. Ag. Sc., BSc., PhD. Executive director (until 30 June 2006) Non-executive director, (from 1 July 2006) Age 57.

Experience and expertise

Chief Executive Officer for nine years until retirement on 1 July 2006. Previously General Manager of the Biomolecular Research Institute. Co-founder, director and major shareholder of a technology based agricultural seed company. Also founder and investor in a number of other start-up technology companies.

Other current directorships None.

Former directorships in last 3 years None.

Special Responsibilities Deputy Chairman Non-executive director of Dendritic Nanotechnologies, Inc. Member of research committee (until 30 June 2006)

Interests in shares and options 5,381,689 ordinary shares in Starpharma Holdings Limited

## **Peter M Colman** BSc(Hons), PhD, FAA, FTSE. Independent non-executive director, Age 62.

Experience and expertise

Non-executive director for nine years. Head, Structural Biology Division, The Walter & Eliza Hall Institute of Medical Research. Former Executive Director, Biomolecular Research Institute. Published widely in the field of structural biology. In 1983 his Laboratory determined the structure of the surface proteins of influenza virus, and a major result of that work was the discovery of Relenza. One of the founding directors of Biota Holdings Limited. *Other current directorships* None.

Former directorships in last 3 years None.

Special Responsibilities Member of research committee. Non-executive director of Dendritic Nanotechnologies, Inc.

Interests in shares and options 5,992,286 ordinary shares in Starpharma Holdings Limited

## Information on Directors (continued)

## **Ross Dobinson** B. Bus (Acc) Independent Non-executive director, Age 54.

## Experience and expertise

Non-executive director for nine years. Merchant banker with a background in investment banking and stockbroking. Has acted as corporate director for two leading stockbrokers, and was an executive director of the NAB's corporate advisory subsidiary. Later headed the Corporate Advisory Division of Dresdner Australia Ltd. Managing Director of TSL Group Ltd, a corporate advisory company specialising in establishing and advising life sciences companies. Also a director of a number of unlisted companies.

## Other current directorships

Non-executive director of two other public companies: Acrux Ltd (director since 2000 and Chairman since 31 January 2006) and Roc Oil Company Limited (director since 1997).

# Former directorships in last 3 years None.

## Special Responsibilities

Chairman of audit & risk management committee. Chairman of remuneration & nomination committee.

Interests in shares and options 2,905,976 ordinary shares in Starpharma Holdings Limited

## Leon Gorr B. Juris, LLB, M.Admin Independent non-executive director, Age 62.

#### Experience and expertise

Non-executive director for five years. Non-executive director of Starpharma Pty Ltd for nine years. Senior Partner, Herbert Geer & Rundle. 33 years' experience as a solicitor. Extensive experience in providing advice on the negotiation and interpretation of technology licensing agreements. Clients include investors in, and advisors to the biotechnology industry. Other current directorships None.

Former directorships in last 3 years None.

Special Responsibilities Member of audit & risk management committee. Member of remuneration & nomination committee.

Interests in shares and options 5,204,704 ordinary shares in Starpharma Holdings Limited

## Information on Directors (continued)

## Peter J Jenkins MB, BS (Melb), FRACP Independent Non-executive director, Age 60.

Experience and expertise

Independent non-executive director for nine years. Consultant physician and gastroenterologist. Holds clinical and research positions with the Alfred Hospital and has held clinical positions with the Baker Medical Research Centre. Former judge of the Australian Technology Awards. Executive Director of AusBio Ltd, an unlisted public biotechnology company.

#### Other current directorships

Non-executive director of bio-pharmaceutical company Anadis Ltd (director since 1994).

Former directorships in last 3 years None.

Special Responsibilities Chairman of research committee. Member of audit & risk management committee.

Interests in shares and options 1,635,608 ordinary shares in Starpharma Holdings Limited

## Jacinth K Fairley B.Sc., B.V.Sc.(Hons), MBA Chief Executive Officer (From 1 July 2006), Age 43.

#### Experience and expertise

Chief Operating Officer of Starpharma from 4 July 2005 to 30 June 2006. Over 15 years' experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Mayne Pharma). Former Chief Executive Officer of Cerylid Biosciences. 5 years as a Vice President for Faulding's injectable division and 5 years with CSL in various executive roles. She holds first class honours degrees in Science (pharmacology/pathology) and Veterinary Science, and has an MBA from the Melbourne Business School where she was the recipient of the Clemenger Medal. Other current directorships None

Former directorships in last 3 years None.

Special Responsibilities Chief Executive Officer Member of research committee (from 1 July 2006)

Interests in shares and options

5,000 ordinary shares in Starpharma Holdings Limited 300,000 options over ordinary shares in Starpharma Holdings Limited

500,000 options over ordinary shares in Starpharma Holdings Limited (subject to shareholder approval at the next Annual General Meeting of the Company)

## **Company Secretary**

The Company Secretary is Mr Ben Rogers. Age 58. He has extensive experience in finance and human resources management with CSIRO research laboratories in Victoria, South Australia and Western Australia. He also operated his own consulting business providing services to Co-operative Research Centres and CSIRO Divisions. Mr Rogers joined Starpharma on commencement of operations in April 1997 and was appointed to the position of Company Secretary in February 1998. He is a member of the senior management team with responsibilities that include the role of Chief Financial Officer.

## **Meetings of Directors**

The number of meetings of the Company's Board of directors and of each committee held during the year ended 30 June 2006, and the numbers of meetings attended by each director were:

Full meetings	s of direc	tors				Meetings o	of com	<u>mittees</u>	
				it & risk nagement		nuneration omination	Rese	earch	Кеу
	А	В	A	В	А	В	A	В	A = Number of meetings attended
P T Bartels	12	13	*	*	3	3	*	*	B = Number of meetings held during
P M Colman	13	13	*	*	*	*	8	9	the time the director held office
R Dobinson	13	13	3	3	3	3	*	*	or was a member of the committee during the year.
L Gorr	11	13	2	3	2	3	*	*	
P J Jenkins	12	13	3	3	*	*	8	9	<ul> <li>Not a member of the relevant committee.</li> </ul>
J W Raff	13	13	*	*	*	*	7	9	

## Retirement, election and continuation in office of Directors

Mr Peter Bartels retires by rotation as director at the annual general meeting and, being eligible, offers himself for re-election.

Dr John Raff retires by rotation as director at the annual general meeting and, being eligible, offers himself for re-election.

Dr Jacinth Fairley was appointed a director on 1 July 2006. In accordance with the Constitution Dr Fairley retires as a director at the annual general meeting and, being eligible, offers herself for re-election.

# Remuneration report

The Remuneration report is set out under the following main headings:

- A. Principles used to determine the
- nature and amount of remuneration B. Details of remuneration
- C. Service Agreements
- D. Share-based compensation
- E. Additional Information

The information provided under headings A–D includes remuneration disclosures that are required under AASB 124 *Related Party Disclosures*. These disclosures have been transferred from the financial report and have been audited. The disclosures in Section E are additional disclosures required by the *Corporations Act 2001* and the *Corporations Regulations 2001* which have not been audited.

## A. Principles used to determine the nature and amount of remuneration

The objective of the company's remuneration policy is to ensure appropriate and competitive reward for the results delivered. The remuneration and nomination committee, consisting of three independent non-executive directors, advises the Board on remuneration policies and practices generally, and makes specific recommendations on remuneration packages and other terms of employment for executive directors, other senior executives and non-executive directors.

## **Directors' fees**

Fees and payments to non-executive directors reflect the demands which are made on, and the responsibilities of, the directors. Non-executive directors' fees consist of a base yearly amount plus additional amounts for membership of board committees or membership of boards of associated entities. The Chairman's fees are determined independently to the fees of non-executive directors based on comparative roles in the external market. The Chairman is not present at any discussions relating to determination of his own remuneration. Nonexecutive directors do not receive share options or bonuses.

Non-executive directors' fees are reviewed annually by the Board, but have not been increased since 1 January 2004. Fees and payments are determined within an aggregate directors' fee pool limit, which is periodically recommended for approval by shareholders. The aggregate amount currently stands at \$350,000 which was approved by shareholders on 19 November 2003. This amount (or some part of it) is to be divided among the non-executive directors as determined by the Board. The aggregate amount currently paid to nonexecutive directors is \$240,000 per annum.

Non-executive directors do not receive any performance-related remuneration.

## **Executive pay**

Remuneration packages are set at levels that are intended to attract and retain executives capable of managing the Group's operations.

The executive pay and reward framework comprises:

- base pay and benefits,
- short term performance incentives,
- long term incentives through participation in the Starpharma Employee Share Option Plan, and
- superannuation.

Factors taken into account in determining remuneration packages include demonstrated record of performance against targets and key performance indicators (KPIs), internal relativities, data from a national biotechnology salary survey and the Company's ability to pay. Service agreements for executives do not include pre-determined bonus or option allocations, but bonuses may be awarded, or options offered at the end of the performance review cycle for specific contributions, or upon achievement of a significant Company milestone at the discretion of the Board and in line with the principles disclosed in the directors' report.

## **Starpharma Employee Share Option Plan**

Information on the Starpharma Employee Share Option Plan is set out in note 36 to the financial statements.

## **Performance review and development**

Executives and all other staff participate in a formal two stage performance review and development process consisting of an objectives planning and development session at the commencement of the annual cycle and a performance and pay review towards the end of the cycle.

## B. Details of remuneration

Details of the nature and amount of each element of the remuneration of each director of Starpharma Holdings Limited and the key management personnel (as defined in AASB 124 *Related Party Disclosures*) of the Company and the consolidated entity are set out in the following tables.

The key management personnel of Starpharma Holdings Limited includes the directors as per pages 21 to 23. The key management personnel of Starpharma Holdings Limited Group includes the directors as per pages 21 to 23 above and the following executive officers, which includes the five highest paid executives of the entity:

N J Baade	J K Fairley	G Y Krippner	J R Paull
C P Barrett	O T Grogan	T D McCarthy	B P Rogers

## Key management personnel of Starpharma Holdings Limited

2006		Shor	-term benefits	Post-employment	Share-based payment	
Name	Cash salary and fees \$	Cash bonus \$	Non-monetary benefits \$	Superannuation \$	Options \$	Total \$
Non-executive directors	S					
P T Bartels Chairman	_	_		80,000	_	80,000
P M Colman	36,697	_		3,303	_	40,000
R Dobinson	40,000	-		_	_	40,000
L Gorr	36,697	_		3,303	_	40,000
P J Jenkins	36,697	_		3,303	_	40,000
Subtotal non-executive directors	150,091			89,909		240,000
Executive directors						
J W Raff	258,500	_	110,420	96,215 <sup>A</sup>	-	465,135
Totals	408,591	-	110,420	186,124	-	705,135

There were no retirement benefits paid during the year ended 30 June 2006.

<sup>A</sup> \$49,983 of \$96,215 contributed to J Raff's superannuation was the result of a bonus.

## B. Details of remuneration (continued)

## Key management personnel of Starpharma Holdings Limited or subsidiary companies

2006		Short-te	rm benefits	Post-employment	Share-based payment	
	Cash salary and fees	N Cash bonus	on-monetary benefits	Superannuation	Options	Total
Name	\$	\$	\$	\$	\$	\$
Non-executive director	s					
P T Bartels Chairman	_	_		80,000	-	80,000
P M Colman	36,697	_		3,303	-	40,000
R Dobinson	40,000	_		_	-	40,000
L Gorr	36,697	_		3,303	-	40,000
P J Jenkins	36,697	_		3,303	-	40,000
Subtotal non-executive directors	150,091			89,909		240,000
Executive directors						
J W Raff	258,500	_	110,420	96,215 <sup>A</sup>	-	465,135
Other Key Managemen	t Personnel					
J K Fairley <sup>1</sup> (from 4/7/05–30/6/06)	233,776	24,000	4,552	38,340 <sup>в</sup>	21,602	322,270
O T Grogan	163,749	_	26,881	28,648	11,962	231,240
B P Rogers	106,681	10,000	34,225	20,991	41,170	213,067
T D McCarthy	119,882	10,000	27,700	32,019 <sup>c</sup>	18,714	208,315
G Y Krippner	103,872	-	25,030	11,187	37,427	177,516
J R Paull	113,088	10,000	4,602	29,411 <sup>D</sup>	14,971	172,072
C P Barrett <sup>2</sup> (from 18/7/05–30/6/06)	102,361	_	_	11,832	7,494	121,687
N J Baade <sup>3</sup> (from 16/1/06–30/6/06)	43,162	_	1,860	7,155	-	52,177
Totals	1,395,162	54,000	235,270	365,707	153,340	2,203,479

There were no retirement benefits paid during the year ended 30 June 2006.

<sup>A</sup> \$49,983 of \$96,215 contributed to J W Raff's superannuation was the result of a bonus.

<sup>B</sup> \$15,000 of \$38,340 contributed to J K Fairley's superannuation was the result of a bonus.

<sup>c</sup> \$10,000 of \$32,019 contributed to T D McCarthy's superannuation was the result of a bonus.

<sup>D</sup> \$10,000 of \$29,411 contributed to J R Paull's superannuation was the result of a bonus.

<sup>1</sup> J K Fairley was appointed Chief Operating Officer on 4 July 2005.

<sup>2</sup> C P Barrett was apponted VP, Business Development on 18 July 2005.

<sup>3</sup> N J Baade was appointed Financial Controller on 16 January 2006.

## B. Details of remuneration (continued)

## Key management personnel of Starpharma Holdings Limited or subsidiary companies

2005		Short-t	erm benefits	Post-employment	Share-based payment	
	Cash salary		Non-monetary			
News	and fees	Cash bonus	benefits	Superannuation	Options	Total
Name	\$	\$	\$	\$	\$	\$
Non-executive director	s					
P T Bartels Chairman	-	-		80,000	-	80,000
P M Colman	36,697	-		3,303	_	40,000
R Dobinson	40,000	_		_	_	40,000
L Gorr	36,697	_		3,303	_	40,000
P J Jenkins	36,697	_		3,303	_	40,000
Subtotal non-executive directors	150,091			89,909		240,000
Executive directors						
J W Raff	269,000	-	78,524	92,350 <sup>A</sup>	_	439,874
Other Key Managemen	t Personnel					
O T Grogan	139,123	-	22,373	21,711	3,589	186,796
A Szabo (1 Jul 04 to 31 Jan 05)	97,964	_	_	8,670	12,966	119,600
B P Rogers	99,666	-	27,368	20,065	43,585	190,684
T D McCarthy	96,421	-	24,897	18,682	19,811	159,811
G Y Krippner	99,346	_	19,920	10,734	39,622	169,622
J R Paull	104,739	_	_	9,426	15,849	130,014
Totals	1,056,350	-	173,082	271,547	135,422	1,636,401

There were no retirement benefits paid during the year ended 30 June 2005.

<sup>A</sup> \$50,000 of \$92,350 contributed to J W Raff's superannuation was the result of a bonus

## C. Service Agreements

Remuneration and other terms of employment for the CEO and the specified executives are formalised in service agreements. Each of these agreements provides for the provision of performance-related cash bonuses, and other benefits

## J W Raff Chief Executive Officer

- Fixed term of three years from 1 September 2004
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$333,218, to be reviewed annually and increased by an amount no less than the annual increase in the Consumer Price Index
- Fringe benefits fully maintained motor vehicle and on-site car parking
- Subject to termination by either party upon the giving of a minimum notice period of one year, except that the Company shall be entitled to terminate the executive's employment summarily in the following circumstances:
  - The Executive wilfully disobeys or disregards a lawful direction given to the Executive or is otherwise guilty of serious misconduct;
  - (ii) The Executive has any direct or indirect interest in any business or matter which conflicts with the proper

including participation, when eligible, in the Starpharma Holdings Employee Option Plan. Other major provisions of the agreements relating to remuneration are set out below.

> performance of the Executive's duties unless the Executive has provided prior written disclosure of such interest and the Company has waived any objection to the Executive maintaining such an interest;

- (iii) The Executive is guilty of any wilful breach or continued neglect of the terms of this Agreement or of the duties and obligations which the Executive is required to perform or meet; or
- (iv) The Executive becomes bankrupt or makes a composition or arrangement with the Executive's creditors generally or takes advantage of any statute for the relief of insolvent debtors such that, in the reasonable opinion of the Company, the performance of the Executive of the Executive's duties and responsibilities is adversely affected or the commercial and business interests of the Company are prejudiced and/or damaged.

## C. Service Agreements (continued)

## J K Fairley Chief Operating Officer

- No fixed term of agreement
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$260,000, to be reviewed annually and increased by an amount no less than the annual increase in the Consumer Price Index
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to six months gross remuneration.

## OT Grogan VP - Commercial Development & Licensing

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$214,675, to be reviewed annually by the remuneration committee.
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to thirteen weeks gross remuneration.

## **B P Rogers** Company Secretary and Chief Financial Officer

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$157,295, to be reviewed annually by the remuneration committee.
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to thirteen weeks gross remuneration.

## T D McCarthy VP – Drug Development

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$180,000, to be reviewed annually by the remuneration committee.
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to thirteen weeks gross remuneration.

## **G Y Krippner** Head of Chemistry

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$145,000, to be reviewed annually by the remuneration committee.
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to thirteen weeks gross remuneration.

## J R Pauli VP – Regulatory and Clinical Affairs

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$145,000, to be reviewed annually by the remuneration committee.
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to thirteen weeks gross remuneration.

## **C P Barrett** VP – Business Development

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$125,725, to be reviewed annually by the remuneration committee.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to thirteen weeks gross remuneration.

## N J Baade Financial Controller

- No fixed term of agreement.
- Base salary, inclusive of superannuation, per annum as at 30 June 2006 of \$110,000, to be reviewed annually by the remuneration committee.
- Fringe benefits on-site car parking.
- Payment of termination benefit on termination by the employer, other than for serious breach of obligations to the employer, wilful neglect of duty or serious misconduct, equal to four weeks gross remuneration.

## D. Share-based compensation

Options are granted under the Starpharma Holdings Limited Employee Share Option Plan (ASX code SPLAM) ("the Plan") which was approved by shareholders at the 2004 annual general meeting. All employees of the Company or associated companies are eligible to participate in the plan. Options are granted under the plan for no consideration. Options are normally granted for a four or five year period and become exercisable on the second anniversary of the date of grant. The terms and conditions of each grant of options affecting remuneration of each director of the company and the key management personnel of the group in this or future reporting periods are as follows:

Grant date	Expiry date	Exercise price	Value per option at grant date	Date exercisable
8 February 2004	8 February 2009	\$0.9375	\$0.46	9 February 2006
12 May 2005	12 May 2010	\$0.9375	\$0.25	13 May 2007
4 July 2005	4 July 2010	\$0.9375	\$0.15	5 July 2007
18 July 2005	18 July 2010	\$0.9375	\$0.16	19 July 2007

Options granted under the Plan carry no dividend or voting rights.

## D. Share-based compensation (continued)

When exercisable, each option is convertible into one ordinary share of the Company to be allotted not more than ten business days after exercise.

## Fair value of options granted

The weighted average assessed fair value at grant date of options granted during the year ended 30 June 2006 was \$0.15 cents per option (2005: \$0.33 cents). The fair value at grant date is independently determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and the expected price volatility of the underlying share, the expected dividend yield and the risk free rate for the term of the option.

Options granted during the year ended 30 June 2006 were:

The weighted average remaining contractual life of share options outstanding at the end of the period was 2.65 years (2005: 2.99 years).

The expected price volatility is based on the historic volatility (based on the remaining life of the options), adjusted for any expected changes to future volatility due to publicly available information.

Options are granted for no consideration, have a four or five year life and become exercisable on the second anniversary of the date of grant.

Options granted on:	4 July 2005	18 July 2005
Number of options granted	300,000	100,000
Expiry date	4 July 2010	18 July 2010
Exercise price	93.75 cents	93.75 cents
Expected price volatility of the company's shares	46.9%	46.9%
Risk-free interest rate	5.2%	5.2%
Expected dividend yield	-	-
Share price at grant date	50 cents	52 cents
Assessed fair value	14.56 cents	15.74 cents

Options granted during the year ended 30 June 2005 were:

Options granted on:	1 July 2004	31 Dec 2004	12 May 2005
Number of options granted	100,000	192,000	100,000
Expiry date	1 July 2009	31 Dec 2009	12 May 2010
Exercise price	93.75 cents	93.75 cents	93.75 cents
Expected price volatility of the company's shares	75.0%	47.6%	46.9%
Risk-free interest rate	5.9%	5.3%	5.7%
Expected dividend yield	_	_	_
Share price at grant date	74 cents	74 cents	66 cents
Assessed fair value	45.00 cents	30.52 cents	25.33 cents

## Shares issues on the exercise of options

No shares in Starpharma Holdings Limited have been issued on the exercise of options in either the current or prior year.

## D. Share-based compensation (continued)

## Share options granted to directors and key management personnel

Details of options over unissued ordinary shares of Starpharma Holdings Limited provided as remuneration to any of the directors or the key management personnel of the Company and consolidated entity with greatest authority as part of their remuneration were as follows:

	Number of options granted	during the year	Number of options vested	Number of options vested during the year	
Name	2006	2005	2006	2005	
C P Barrett	100,000	-	_	_	
J K Fairley	300,000	_	-	_	
O T Grogan	-	100,000	-	_	
G Y Krippner	-	_	200,000	_	
T D McCarthy	-	_	100,000	_	
J R Paull	-	_	80,000	_	
B P Rogers	-	_	220,000	_	

The options were granted under the Starpharma Holdings Limited Employee Share Option Plan on the dates indicated. Details of options granted to the directors and the five most highly remunerated officers of the Group can be found in section D of the remuneration report on page 29. No options have been granted since the end of the year.

No other directors or key management personnel hold options under the Plan.

500,000 Employee Share Options were offered to Dr J K Fairley subject to shareholder approval at the next Annual General Meeting of the Company.

The options will be granted in accordance with the terms of the Company's Employee Share Option Plan and will include the following terms and conditions:

- Issue price: nil.
- Exercise price: 45.08 cents per share (determined on the basis of market value plus 15%. Market value is based on a 15 day volume weighted average price of the Company's shares prior to 1 July 2006, the date of appointment of the Executive to the position of CEO).
- Exercise period: From 1 July 2007 to 30 June 2009.

## E. Additional Information - Unaudited

# Principles used to determine the nature and amount of remuneration: relationship between remuneration and company performance

Policies are structured to reward performance that could reasonably be expected to increase shareholder value, and the performance of the Company over the current and prior year is taken into account in determining overall levels of executive reward. As the company is in a research and development phase and is not generating earnings, service agreements for executives do not include pre-determined bonus or share option allocations. Bonuses may be awarded or options offered for outstanding performance that contributes to achievement of specific milestones. Further details of the company's remuneration policy are set out in Section A of the Remuneration Report on page 25.

Further details relating to options are set out below.

Name	A Remuneration consisting of options	B Value at grant date \$	C Value at exercise date \$	D Value at lapse date \$	E Total of columns B to D \$
J K Fairley	14.97%	45,000	_	_	45,000
O T Grogan	_	_	_	_	_
B P Rogers	_	_	_	_	_
T D McCarthy	_	_	_	_	_
G Y Krippner	_	_	_	_	_
J R Paull	_	_	_	_	_
C P Barrett	14.01%	16,000	_	_	16,000
N J Baade	-	_	_	_	_

## E. Additional Information - Unaudited (continued)

- A = The percentage of the value of remuneration consisting of options, based on the value at grant date set out in column B.
- B = The value at grant date calculated in accordance with AASB 2 *Share-based payments* of options granted during the year as part of remuneration.
- C = The value at exercise date of options that were granted

## Details of remunerations: cash bonuses and options

For each cash bonus and grant of options included in the tables on pages 26 to 31, the percentage of the available bonus or grant that was paid, or that vested, in the financial year, and the percentage that was forfeited because the person did not meet the service and performance criteria is set out below. No part of the bonuses is payable in future years. as part of remuneration and were exercised during the year.

D = The value at lapse date of options that were granted as part of remuneration and that lapsed during the year.

The options vest over the specified periods providing vesting criteria are met. No options will vest if the conditions are not satisfied, hence at 30 June 2006 the minimum value of the options yet to vest is nil. The maximum value of the options yet to vest has been determined assuming all conditions are met.

#### Cash bonus Options Financial years in Minimum total Maximum total Paid Forfeited Forfeited which options value of grant Year Vested value of grant Name % Granted yet to vest yet to vest % % % may vest J W Raff 100 \_ \_ \_ \_ \_ \_ \_ J K Fairley 100 2006 30/06/2008 nil 22,081 \_ \_ 2003 100 O T Grogan nil nil \_ \_ \_ 2005 30/06/2007 nil 10.356 **B P Rogers** 2004 100 50 nil nil \_ \_ T D McCarthy 100 2004 100 nil nil \_ \_ **G** Y Krippner 2004 100 \_ \_ \_ nil nil J R Paull 100 2004 100 nil nil \_ \_ C P Barrett 2006 30/06/2008 8,248 \_ \_ \_ nil N J Baade \_ \_ \_ \_ \_ \_

## E. Additional Information - Unaudited (continued)

## **Shares under option**

Unissued ordinary shares of Starpharma Holdings Limited under option at the date of this report are as follows:

Date options granted	Expiry date	Issue price of shares	Number under option
12 April 2002	11 April 2007	\$0.9375	220,000
21 June 2002	30 June 2007	\$0.9375	200,000
6 February 2004	31 December 2008	\$0.7300	200,000
8 February 2004	8 February 2009	\$0.9375	720,000
31 December 2004	31 December 2009	\$0.9375	167,000
12 May 2005	12 May 2010	\$0.9375	100,000
4 July 2005	4 July 2010	\$0.9375	300,000
18 July 2005	18 July 2010	\$0.9375	100,000
		Total:	2,007,000

No option holder has any right under the options to participate in any other issue of the company or of any other entity.

## **Insurance of officers**

During the financial year, Starpharma Holdings Limited arranged to insure the directors and executive officers of the Company and related bodies corporate. The terms of the policy prohibit disclosure of the amount of the premium paid.

The liabilities insured are legal costs that may be incurred in defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of entities in the Group, and any other payments arising from liabilities incurred by the officers in connection with such proceedings. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for themselves or someone else or to cause detriment to the company.

## Audit & non audit services

The Company may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the Company and/or the consolidated entity are important.

Details of the amounts paid or payable to the auditor (PricewaterhouseCoopers) for audit and non-audit services provided during the year are set out below.

## Audit & non audit services (continued)

The board of directors has considered the position and, in accordance with the advice received from the audit and risk management committee is satisfied that the provision of the non-audit services is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*. The directors are satisfied that the provision of non-audit services by the auditor, as set out below, did not compromise the auditor independence requirements of the *Corporations Act 2001* for the following reasons:

- all non-audit services have been reviewed by the audit & risk management committee to ensure they do not impact the impartiality and objectivity of the auditor
- none of the services undermine the general principles relating to auditor independence as set out in Professional Statement F1, including reviewing or auditing the auditor's own work, acting in a management or a decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risk and rewards.

During the year the following fees were paid or payable for services provided by the auditor (PricewaterhouseCoopers) of the parent entity, its related practices and non-related audit firms:

No taxation or advisory services have been provided in either the current or prior year.

Assurance Services	2006 \$	2005 \$
Audit or review of financial reports of the entity or any entity in the consolidated entity under the <i>Corporations Act 2001</i>	114,990	92,500
Other assurance services:- Grant reviews & program audits	7,500	22,000

## **Auditors' Independence Declaration**

A copy of the auditors' independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 35.

## Auditor

PricewaterhouseCoopers continues in office in accordance with section 327 of the *Corporations Act 2001*.

This report is made in accordance with a resolution of the Directors.

Peter T Bartels, AO Director 26th September 2006 Melbourne

# PRICEWATERHOUSE COOPERS 12

#### PricewaterhouseCoopers ABN 52 780 433 757

Freshwater Place 2 Southbank Boulevard SOUTHBANK VIC 3006 GPO Box 1331L MELBOURNE VIC 3001 DX 77 Website:www.pwc.com/au Telephone 61 3 8603 1000 Facsimile 61 3 8603 1999

## Auditor's Independence Declaration

As lead auditor for the audit of Starpharma Holdings Limited for the year ended 30 June 2006, I declare that to the best of my knowledge and belief, there have been:

- a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b) no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Starpharma Holdings Limited and the entities it controlled during the period.

Pricurate house Cogeros

PricewaterhouseCoopers

SC Bannatyne Partner

Melbourne 26 September 2006

Liability limited by a scheme approved under Professional Standards Legislation

# **Corporate Governance Statement**

Starpharma Holdings Limited (the Company) and the Board are committed to achieving and demonstrating the highest standards of corporate governance. The Board guides and monitors the Company's activities on behalf of the shareholders. In developing policies and setting standards the Board considers the ASX Corporate Governance Council's *Principles of Good Corporate Governance and Best Practice Recommendations* ("the ASX Recommendations"). The Corporate Governance Statement set out below describes

### 1. The Board of Directors

The relationship between the Board and senior management is critical to the Group's long term success. The directors are responsible to the shareholders for the performance of the Group in both the short and the longer term and seek to balance sometimes competing objectives in the best interests of the Group as a whole. Their focus is to enhance the interests of shareholders and other key stakeholders and to ensure the Group is properly managed.

Day to day management of the Group's affairs and the implementation of the corporate strategy and policy initiatives are delegated by the Board to the Chief Executive Officer ("CEO") and senior executives. These delegations are reviewed on an annual basis.

### 1.1 Board charter

The Board composition and responsibilities are set out in the Board charter, which may be viewed in the Corporate Governance section of the Company's website.

### **1.2 Board meetings**

Board meetings are held on a monthly basis, or more frequently if required. A detailed management report is prepared by senior management and distributed with board papers prior to each meeting. The CEO and the Company Secretary attend all Board meetings.

### **1.3 Board members**

Details of the members of the Board, their experience, qualifications, term of office and independent status are set out in the directors' report under the heading "Information on Directors". There are six non-executive directors, five of whom are deemed independent under the principles set out below, and one executive director at the date of signing the directors' report. The composition of the Board changed on 1 July 2006 when Dr J K Fairley was appointed as a director and Dr J W Raff reverted to a non-executive capacity.

The Board seeks to ensure that:

- at any point in time, its membership represents an appropriate balance between directors with experience and knowledge of the Group and directors with an external or fresh perspective; and
- the size of the Board is conducive to effective discussion and efficient decision-making.

the Company's current corporate governance practices which the Board considers to substantially accord with the ASX Recommendations.

All these practices, unless otherwise stated, were in place for the entire year. This corporate governance statement is available on the Company's website. A table at the end of this statement provides a cross-reference of relevant sections of the statement against the ASX Recommendations.

### 1.4 Directors' independence

The Company has adopted the criteria for assessing the independence of a director as set out in the ASX Recommendations. Materiality for the purposes of applying these criteria is determined on both quantitative and qualitative bases. An amount of 5% of the individual director's net worth is considered material, and in addition a transaction of any amount or a relationship is deemed material if knowledge of it may impact the shareholders' understanding of the director's performance. A director is also not considered independent if he has a substantial shareholding as defined in section 9 of the *Corporations Act* or if he has been employed in an executive capacity within the last three years. Under these criteria the Board has determined that all non-executive directors were independent at the date of this report with the exception of Dr J W Raff, who was an executive director until 30 June 2006.

### 1.5 Term of office

The Company's Constitution requires that one third of nonexecutive directors (or if their number is not a multiple of three then the number nearest to one third) retire at every annual general meeting and be eligible for re-election.

### **1.6 Chairman and Chief Executive Officer**

The Chairman is responsible for leading the Board, ensuring directors are properly briefed in all matters relevant to their role and responsibilities, facilitating Board discussions and managing the Board's relationship with the Group's senior executives. The CEO is responsible for implementing Group strategies and policies. The Board policy is for these separate roles to be undertaken by separate people.

### **1.7 Commitment**

Board meetings are held on a monthly basis, or more frequently if required. Meetings are held at the Company's corporate offices and laboratory facility in the Baker Building, 75 Commercial Road, Melbourne. The number of meeting of the Board and of each Board committee held during the year ended 30 June 2006, and the number of meetings attended by each director is disclosed in the Directors' Report. The commitments of non-executive directors are considered by the remuneration and nomination committee prior to the directors' appointments to the Board and are reviewed each year as part of the annual performance assessment.

### 1. The Board of Directors (continued)

### 1.7 Commitment (cotinued)

Prior to appointment or being submitted for re-election each non-executive director is required to specifically acknowledge that they have and will continue to have the time available to discharge their responsibilities to the Company.

#### **1.8 Conflict of interests**

Directors are expected to avoid any action, position or interest that results in a conflict with an interest of the Company. A director who has a material personal interest in a matter that relates to the affairs of the Company must give notice of such interest.

### 1.9 Independent professional advice

Directors and Board committees have the right, in connection with their duties and responsibilities, to seek independent professional advice at the Company's expense. Prior approval of the Chairman is required, but this approval will not be unreasonably withheld.

#### 1.10 Performance assessment

The Board undertakes an annual assessment of Board performance. Each director completes a questionnaire on matters such as composition, structure, and role of the Board and performance of individual directors. These questionnaires are reviewed by the remuneration & nomination committee and the Chairman then meets individually with each director to discuss the assessment.

### 2. Corporate reporting

The CEO and the CFO have made the following certifications to the Board:

- that the Company's financial reports are complete and present a true and fair view, in all material respects, of the financial condition and operational results of the Company and Group and are in accordance with relevant accounting standards; and
- that the above statement is founded on a sound system of risk management and internal compliance and control and which implements the policies adopted by the Board and that the Company's risk management and internal compliance and control is operating efficiently and effectively in all material respects.

The Company adopted this reporting structure for the year ended 30 June 2006.

### 3. Board committees

The Board has established a number of committees to assist in the execution of its duties and to allow detailed consideration of complex issues. The committee structure and membership is reviewed on an annual basis. Board committees are chaired by an independent director other than the Chairman of the Board. Minutes of committee meetings are tabled at the following Board meeting, and all matters determined by committees are submitted to the full Board as recommendations for Board decisions. Current committees of the Board are the following:

### 3.1 Audit and risk management committee

The audit and risk management committee consists of the following independent non-executive directors:

Mr Ross Dobinson (Chairman) Mr Leon Gorr Dr Peter Jenkins

Details of these directors' qualifications and attendance at committee meetings are set out in the directors' report pages 21 to 24.

The audit and risk management committee has appropriate financial expertise and all members are financially literate and have an appropriate understanding of the industry in which the Group operates.

The committee meets at least twice a year, and has direct access to the Company's auditors. The charter of this committee is to:

 review and report to the Board on the annual report, the halfyear financial report and all other financial information published by the company or released to the market

- assist the Board in reviewing the effectiveness of the organisation's internal control environment covering:
  - > effectiveness and efficiency of operations
  - reliability of financial reporting
  - > compliance with applicable laws and regulations
- oversee the effective operation of the risk management framework by:
  - ensuring the effective implementation of the risk management policy and program
  - > defining risk threshold levels for referral to the Board
  - ensuring that an effective system of internal compliance and control is in place
  - ensuring staff charged with risk management responsibilities have appropriate authority to carry out their functions and have appropriate access to the audit and risk management committee
  - ensuring the allocation of sufficient resources for the effective management of risk
- recommend to the Board the appointment, removal and remuneration of the external auditors, and review the terms of their engagement, the scope and quality of the audit and assess performance
- consider the independence and competence of the external auditor on an ongoing basis
- review and monitor related party transactions and assess their propriety
- assist the Board in the development and monitoring of statutory compliance and ethics programs
- provide assurance to the Board that it is receiving adequate, up to date and reliable information
- oversee the Group's transition to Australian equivalent to International Financial Reporting Standards (AIFRS)
- report to the Board on matters relevant to the committee's role and responsibilities.

### 3. Board committees (continued)

### 3.2 Remuneration and nomination committee

The remuneration and nomination committee consists of the following independent non-executive directors:

Mr Ross Dobinson (Chairman) Mr Peter Bartels Mr Leon Gorr

Details of these directors' attendance at committee meetings are set out in the directors' report on pages 21 to 24.

The main responsibilities of the committee are to:

- conduct annual reviews of board membership having regard to present and future needs of the Company and make recommendations on board composition and appointments
- conduct an annual review of and conclude on the independence of each director
- propose candidates for board vacancies
- oversee board succession including the succession of the Chairman
- oversee the annual assessment of board performance
- advise the board on remuneration and incentive policies and practices generally
- make specific recommendations on remuneration packages and other terms of employment for executive directors, other senior executives and non-executive directors.

When the need for a new director is identified or an existing director is required to stand for re-election, the committee reviews the range of skills, experience and expertise on the board, identifies its needs and prepares a short-list of candidates with appropriate skills and experience. Where necessary, advice is sought from independent search consultants.

Each member of the senior executive team has signed a formal employment contract covering a range of matters including their duties, rights, responsibilities and any entitlements on termination. The standard contract refers to a specific formal position description.

The remuneration and nomination committee's terms of reference include responsibility for reviewing any transaction between the organisation and the directors, or any interest associated with the directors, to ensure the structure and the terms of the transaction are in compliance with the *Corporations Act 2001* and are appropriately disclosed.

The Remuneration Report is set out on pages 25 to 33.

#### 3.3 Research committee

The research committee consists of the following directors:

#### Dr Peter Jenkins (Chairman)

Independent non-executive director

#### **Dr Jackie Fairley**

Chief Executive Officer and director (From 1 July 2006)

#### **Prof Peter Colman**

Independent non-executive director

Dr John Raff (Until 30 June 2006)

#### Director

(Chief Executive Officer until 30 June 2006)

The charter of the research committee is:

- to ensure that the Board is kept fully informed of developments relating to the Company's research activities and development progress against milestones; and
- to advise the Board on scientific matters in relation to the Company's continuous disclosure obligations under the listing rules of the Australian Stock Exchange Limited.

### 4. External auditors

The Company's policy is to appoint external auditors who clearly demonstrate quality and independence. The performance of the external auditor is reviewed annually. PricewaterhouseCoopers were appointed as the external auditors at the commencement of the Company's operations in 1996. It is PricewaterhouseCoopers policy to rotate audit engagement partners on listed companies at least every five years, and the current audit engagement partner assumed responsibility for the conduct of the audit in 2005.

### 5. Risk assessment and management

The Board, through the audit and risk management committee, is responsible for ensuring there are adequate policies in relation to risk management, compliance and internal control systems. The Company operates in a challenging and dynamic environment, and risk management is viewed as integral to realising new opportunities as well as identifying issues that may have an adverse effect on the Company's existing operations and its sustainability. The Board is committed to a An analysis of fees paid to the external auditors, including a break-down of fees for non-audit services, is provided in note 27 to the financial statements. It is the policy of the external auditors to provide an annual declaration of their independence to the audit and risk management committee.

The external auditor is requested to attend the annual general meeting and be available to answer shareholder questions about the conduct of the audit and the preparation and content of the audit report.

proactive approach in managing material business risks, and it aims to ensure that effective risk management practices are a key element of the Company's culture. The risk management policy, which is available on the Company website, sets out the responsibilities and authorities of the Board, the audit and risk management committee, the CEO and Company Secretary, and the senior management team. The Company Secretary is responsible to the Board for the overall implementation of the risk management program.

### 6. The environment, occupational health and safety

The Company recognises the importance of environmental issues and is committed to the highest levels of performance. There are adequate systems in place to ensure compliance with Commonwealth and State environmental regulations and the directors are not aware of any breach of applicable environmental regulations. The Company has adopted an Occupational Health and Safety (OH&S) Policy and has established an OH&S committee as part of its overall approach to workplace safety. This committee meets monthly to review the development and implementation of OH&S policy and procedures, to consider any work related safety matters or incidents, and to ensure compliance with relevant legislation and guidelines. The CEO is represented on the OH&S committee by the Company Secretary.

### 7. Code of conduct

The Company has adopted a code of conduct reflecting the core values of the Company and setting out the standards of ethical behaviour expected of directors, officers and employees in all dealings and relationships including with shareholders, contractors, customers and suppliers, and with the Company. The code of conduct is available in the Corporate Governance section of the Company's website.

### 8. Ethical standards

The directors are committed to the principles underpinning best practice in corporate governance, with a commitment to the highest standards of legislative compliance and financial and ethical behaviour.

### 9. Trading in Company securities

The purchase and sale of Company securities by directors, executives and employees is only permitted (subject to also complying with applicable laws) during the thirty day period following the annual general meeting and the release of the half yearly and annual financial results to the market, unless prior approval is given to each transaction by the Chairman. Except with the prior approval of the Chairman, no director or executive may enter into any transaction which would have the effect of hedging or otherwise transferring to any other person the risk of any fluctuation in the value of:

- (a) securities in the Company which are subject to a restriction on disposal under an employee share or incentive plan; or
- (b) options or performance rights (or any unvested securities in the Company underlying them).

The Company's share trading policy is discussed with each new employee as part of their induction training.

### 10. Continuous disclosure and shareholder communication

The Board has appointed the Company Secretary as the person responsible for disclosure of information to the Australian Stock Exchange Limited (ASX). This role includes responsibility for ensuring compliance with the continuous disclosure requirements of the ASX Listing Rules and overseeing and coordinating information disclosure to the ASX, analysts, brokers, shareholders, the media and the public. All ASX announcements are posted on the Company's web site as soon as practicable after release to the ASX. Procedures have been established for reviewing whether there is any price sensitive information that should be disclosed to the market, or whether any price sensitive information may have been inadvertently disclosed.

## 11. Reporting against ASX Recommendations

The following table cross-references the Company's corporate governance statement against the ASX Recommendations. The full text of the ASX Recommendations is available from http://www.asx.com.au/CorporateGovernance.

Recommendation	Details	Corporate Governance Statement section
1.1	Functions of the Board and management	1.1
2.1	Independent directors	1.4
2.2	Independent chairperson	1.4
2.3	Role of the Chairman and CEO	1, 1.1, 1.6
2.4	Nomination Committee	3.2
2.5	Reporting on Principle 2	1.1–1.10
3.1	Code of conduct	7
3.2	Company security trading policy	9
3.3	Reporting on Principle 3	11
4.1	Attestations by CEO and CFO	2
4.2	Audit committee	3.1
4.3	Structure of audit committee	3.1
4.4	Audit committee charter	3.1
4.5	Reporting on Principle 4	3.1, 11
5.1	Continuous disclosure	10
5.2	Reporting on Principle 5	Introduction, 11
6.1	Communications strategy	10
6.2	Auditor to attend general meetings	4
7.1	Risk oversight and management	2,5
7.2	CEO and CFO statements	2
7.3	Reporting on Principle 7	Introduction, 11
8.1	Performance evaluation of Board and executives	1.10, 3.2
9.1	Remuneration disclosures	3.2
9.2	Remuneration committee	3.2
9.3	Executive and non-executive directors' remuneration	3.2
9.5	Reporting on Principle 9	3.2
10.1	Company code of conduct	7

# **Annual Financial Report**

30 June 2006

Contents	
Income statements	42
Balance sheets	43
Statements of changes in equity	44
Cash flow statements	45
Notes to the financial statements	46
Directors' declaration	77
Independent audit report to the members	78

This financial report covers both Starpharma Holdings Limited as an individual entity and the consolidated entity consisting of Starpharma Holdings Limited and its subsidiaries. The financial report is presented in the Australian currency.

Starpharma Holdings Limited is a company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Starpharma Holdings Limited Baker Building, 75 Commercial Road Melbourne, Victoria, 3004, Australia A description of the nature of the consolidated entity's operations and its principal activities is included in the review of operations on pages 2–18 and in the directors' report on pages 19–34, both of which are not part of the financial report.

The financial report was authorised for issue by the directors on 26th September 2006. The company has the power to amend and reissue the financial report.

# Income statements

For the year ended 30 June 2006

		Consolidated			Parent Entity
	Notes	2006 \$	2005 \$	2006 \$	2005 \$
Revenue from continuing operations	5	571,837	639,454	526,606	601,679
Other income	6	6,422,066	1,409,844	_	
Administration expense		(3,906,186)	(3,541,814)	(2,037,530)	(1,118,152)
Research and development expense		(9,945,396)	(7,007,693)	-	_
Provision for diminution		_	_	(7,996,332)	(6,912,407)
Finance costs		(23,285)	(8,290)	-	_
Share of results of associates accounted for using the equity method		(641,825)	760,708	_	_
Loss before income tax		(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Income tax expense	8	_	_	_	_
Loss for the year		(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Loss attributable to minority interests		-	_	-	_
Loss attributable to members of Starpharma Holdings Limited		(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Loss per share for loss from continuing operations attributable to the ordinary equity holders of the company					
Basic loss per share	35	(5.69) cents	(6.97) cents		
Diluted loss per share	35	(5.69) cents	(6.97) cents		

The above income statements should be read in conjunction with the accompanying notes.

# **Balance Sheets**

As at 30 June 2006

		Consolidated		Consolidated	ed Parent Entit
		2006	2005	2006	2005
	Notes	\$	\$	\$	\$
Current assets					
Cash and cash equivalents	9	14,283,824	8,166,259	12,361,134	6,322,524
Trade and other receivables	10	2,824,267	187,656	94,292	91,087
Total current assets		17,108,091	8,353,915	12,455,426	6,413,611
Non-current assets					
Receivables	11	-	_	-	_
Property, plant and equipment	14	1,431,124	1,232,764	-	-
Intangible assets	15	4,086,538	_	4,086,538	-
Investments accounted for using the equity method	12	2,387,312	2,913,061	_	-
Other financial assets	13	-	_	5,208,750	5,368,747
Total non-current assets		7,904,974	4,145,825	9,295,288	5,368,747
Total assets		25,013,065	12,499,740	21,750,714	11,782,358
Current liabilities					
Trade and other payables	16	1,897,819	1,647,182	1,484,154	765,276
Provisions	18	331,447	279,589		
Borrowings	17	142,092	60,007	_	_
Deferred Income	19	661,337	378,063		_
Total current liabilities		3,032,695	2,364,841	1,484,154	765,276
Non-current liabilities		-,,	_,	-,	
Borrowings	20	315,412	79,750		_
Provisions	21	107,630	89,184		
Deferred Income	22	241,342			
Total non-current liabilities		664,384	168,934		
Total liabilities		3,697,079	2,533,775	1,484,154	765,276
Net assets		21 215 006	0.005.005	20.266.560	11 017 000
		21,315,986	9,965,965	20,266,560	11,017,082
Equity					
Contributed equity	23	65,375,467	46,821,956	65,375,467	46,821,956
Reserves	24	497,374	178,076	421,838	218,615
Accumulated losses	25	(44,556,855)	(37,034,067)	(45,530,745)	(36,023,489)
Total equity		21,315,986	9,965,965	20,266,560	11,017,082

The above balance sheets should be read in conjunction with the accompanying notes.

# Statements of changes in equity For the year ended 30 June 2006

		Consolidated		P	Parent Entity
	Notes	2006 \$	2005 \$	2006 \$	2005 \$
Total equity at the beginning of the year		9,965,965	17,592,496	11,017,082	18,284,163
Exchange differences on translation of foreign operations	24	116,075	(40,539)	_	_
Net income recognised directly in equity		116,075	(40,539)	-	_
Profit (loss) for the year		(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Total recognised income and expense for the year		(7,406,714)	(7,788,330)	(9,507,256)	(7,428,880)
Transactions with equity holders in their capacity as equity holders:					
Employee share options	24	203,223	161,799	203,223	161,799
Contributions of equity, net of transaction costs	23	18,553,512	_	18,553,512	_
Total equity at the end of the year		21,315,986	9,965,965	20,266,560	11,017,082

The above statements of changes in equity should be read in conjunction with the accompanying notes.

# Cash flow Statements For the year ended 30 June 2006

		C	onsolidated	F	Parent Entity
	NULL	2006	2005	2006	2005
Cook flow from an exeting potivities	Notes	\$	\$	\$	\$
Cash flow from operating activities					
Receipts from trade and other debtors		110	23,411	-	13,772
Grant Income (inclusive of GST)		4,360,527	1,787,906	_	_
Payments to suppliers and employees (inclusive of GST)		(12,405,980)	(8,253,163)	(1,046,208)	(1,123,803)
Interest received		574,151	641,547	538,295	610,391
Interest paid		(18,756)	(8,290)	_	_
Net cash outflows from operating activities	33	(7,489,948)	(5,808,589)	(507,913)	(499,640)
Cash flow from investing activities					
Equity investment		_	(1,500,699)	_	(1,500,699)
Loans advanced to subsidiaries		-	_	(7,683,238)	(6,750,608)
Loans advanced from subsidiaries		-	_	50,129	259,294
Repayment of loans advanced to associated entity		_	286,306	_	289,608
Receipts from property, plant and equipment		25,904	_	_	_
Payments for property, plant and equipment		(463,184)	(405,294)	_	_
Net cash outflows from investing activities		(437,280)	(1,619,687)	(7,633,109)	(7,702,405)
Cash flows from financing activities		·			
Proceeds from issue of shares		14,990,045	_	14,990,045	_
Share issue transaction costs		(810,413)	_	(810,413)	_
Payments of finance leases		(134,839)	(63,765)	_	_
Net cash inflows (outflows) from financing activities		14,044,793	(63,765)	14,179,632	-
Net increase (decrease) in cash and cash equivalents held		6,117,565	(7,492,041)	6,038,610	(8,202,045)
Cash and cash equivalents at the beginning of the period		8,166,259	15,658,300	6,322,524	14,524,569
Cash and cash equivalents at the end of the period	9	14,283,824	8,166,259	12,361,134	6,322,524

The above cash flow statements should be read in conjunction with the accompanying notes.

# Notes to the financial statements

30 June 2006

### Contents

		Page
1.	Summary of significant accounting policies	47
2.	Financial Risk Management	52
3.	Critical accounting estimates and judgments	52
4.	Segment information	52
5.	Revenue	53
6.	Other income	53
7.	Expenses	53
8.	Income tax expense	54
9.	Current assets – Cash and cash equivalents	55
10.	Current assets – Trade and other receivables	55
11.	Non-current assets – Receivables	56
12.	Non-current assets – Investments accounted for using the equity method	56
13.	Non-current assets – Other financial assets	57
14.	Non-current assets – Property, plant and equipment	57
15.	Non-current assets – Intangible assets	58
16.	Current liabilities – Trade and other payables	58
17.	Current liabilities – Borrowings	58
18.	Current liabilities – Provisions	59
19.	Current liabilities – Deferred Income	59
20.	Non-current liabilities – Borrowings	59
21.	Non-current liabilities – Provisions	59
22.	Non-current liabilities – Deferred Income	59
23.	Contributed equity	60
24.	Reserves	60
25.	Accumulated Losses	61
26.	Key management personnel disclosures	61
27.	Remuneration of auditors	65
28.	Contingencies	65
29.	Commitments	65
30.	Subsidiaries	67
31.	Investments in associates	68
32.	Events occurring after the balance sheet date	69
33.	Reconciliation of profit after income tax to net cash inflow from operating activities	70
34.	Non-cash financing activities	70
35.	Earnings per share	70
36.	Share-based payments	71
37.	Related party transactions	73
38.	Explanation of transition to Australian equivalents to IFRSs	74

### 1. Summary of significant accounting policies

The principal accounting policies adopted in the preparation of the financial report are set out below. These policies have been consistently applied to all periods presented, unless otherwise stated. The financial report includes separate financial statements for Starpharma Holdings Limited as an individual entity and the consolidated entity consisting of Starpharma Holdings Limited and its subsidiaries.

#### (a) Basis of preparation

This general purpose financial report has been prepared in accordance with Australian equivalents to International Financial Reporting Standards (AIFRS), other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the *Corporations Act 2001.* 

#### **Compliance with IFRSs**

Australian Accounting Standards include AIFRS. Compliance with AIFRS ensures that the consolidated financial statements and notes of Starpharma Holdings Limited comply with international Financial Reporting Standards (IFRSs). The parent entity financial statements and notes also comply with IFRSs except that is has elected to apply the relief provided to parent entities in respect of certain disclosure requirements contained in AASB 132 *Financial Instruments: Presentation and Disclosure*.

Application of AASB 1 *First-time Adoption of Australian Equivalents to International Financial Reporting Standards* (AIFRS)

These financial statements are the first Starpharma Holdings Limited financial statements to be prepared in accordance with AIFRS. AASB 1 *First time Adoption of Australian Equivalents to International Financial Reporting Standards* has been applied in preparing these financial statements.

Financial statements of Starpharma Holdings Limited until 30 June 2005 had been prepared in accordance with previous Australian Generally Accepted Accounting Principles (AGAAP). AGAAP differs in certain respects from AIFRS. When preparing the Starpharma Holdings Limited 2006 financial statements, management has amended certain accounting, valuation and consolidation methods applied in the previous AGAAP financial statements to comply with AIFRS. With the exception of financial instruments, the comparative figures in respect of 2005 were restated to reflect these adjustments. The Group has taken the exemption available under AASB 1 to only apply AASB 132 *Financial Instruments: Disclosure and Presentation* and AASB 139 *Financial Instruments: Recognition and Measurement* from 1 July 2005.

Reconciliations and descriptions of the effect of transition from previous AGAAP to AIFRS on the Group's equity and its net income are given in note 38.

#### Historical cost convention

These financial statements have been prepared under the historical cost convention.

#### (b) Principles of consolidation

#### (i) Subsidiaries

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Starpharma Holdings Limited ("company" or "parent company") as at 30 June 2006 and the results of all subsidiaries for the year then ended. Starpharma Holdings Limited and its subsidiaries together are referred to in this financial report as the Group or the consolidated entity. Subsidiaries are all those entities (including special purpose entities) over which the Group has power to govern the financial and operating policies, generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Group controls another entity.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

The purchase method of accounting is used to account for the acquisition of subsidiaries by the Group (refer to note 1(i)).

Intercompany transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Minority interests in the results and equity of subsidiaries are shown separately in the consolidated income statement and balance sheet respectively.

Investments in subsidiaries are accounted for at cost in the individual financial statements of Starpharma Holdings Limited.

#### (ii) Associates

Associates are all entities over which the Group has significant influence but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for in the parent entity financial statements using the cost method and in the consolidated financial statements using the equity method of accounting, after initially being recognised at cost. The Group's investment in associates includes goodwill (net of any accumulated impairment loss) identified on acquisition

The Group's share of its associates' post-acquisition profits or losses is recognised in the income statement, and its share of post-acquisition movements in reserves is recognised in reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Dividends receivable from associates are recognised in the parent entity's income statement, while in the consolidated financial statements they reduce the carrying amount of the investment.

When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate.

Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in the associates. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been changed where necessary to ensure consistency with the policies adopted by the group.

### (c) Segment reporting

A business segment is a group of assets and operations engaged in providing products or services that are subject to risks and returns that are different to those of other business segments. A geographical segment is engaged in providing products or services within a particular economic environment and is subject to risks and returns that are different to those of segments operating in other economic environments.

### (d) Foreign currency translation

#### (i) Functional and presentation currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The consolidated financial statements are presented in Australian dollars, which is Starpharma Holdings Limited's functional and presentation currency.

#### (ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

#### (iii) Group companies

Assets and liabilities of associated entities are translated into Australian currency at rates of exchange current at balance date, while their incomes and expenses are translated at the average of rates during the year. Exchange differences arising on translation are taken to the foreign currency translation reserve.

### (e) Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances and amounts collected on behalf of third parties. Interest revenue is recognised on a time proportion basis using the effective interest rate method.

All revenue is stated net of the amount of Goods and Services Tax (GST).

### (f) Government Grants

Government grants include contract income awarded by government bodies for research and development projects.

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

Government grants relating to costs are deferred and recognised in the income statement over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to the purchase of property, plant and equipment are included in non-current liabilities as deferred income and are credited to the income statement on a straight line basis over the expected lives of the related assets.

### (g) Income Tax

The income tax expense or revenue for the period is the tax payable on the current period's taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity.

Starpharma Holdings Limited and its wholly-owned Australian controlled entities have not implemented the tax consolidation legislation.

#### (h) Leases

Leases of plant and equipment where the Group has substantially all the risks and rewards of ownership are classified as finance leases (note 29). Finance leases are capitalised at the lease's inception at the lower of the fair value of the leased property and the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, are included in other long term payables. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to the income statement over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The plant and equipment acquired under finance leases is depreciated over the shorter of the asset's useful life and the lease term.

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases (note 29). Payments made under operating leases (net of any incentives received from the lessor) are charged to the income statement on a straight-line basis over the lease term.

Lease income from operating leases is recognised in income on a straight-line basis over the lease term.

### (i) Business combinations

The purchase method of accounting is used to account for all business combinations, including business combinations involving entities or businesses under control, regardless of whether equity instruments or other assets are acquired. Cost is measured as the fair value of the assets given, shares issued or liabilities incurred or assumed at the date of exchange plus costs directly attributable to the acquisition. Where equity instruments are issued in an acquisition, the fair value of the instruments is their published market price as at the date of exchange unless, in rare circumstances, it can be demonstrated that the published price at the date of exchange is an unreliable indicator of fair value and that other evidence and valuation methods provide a more reliable measure of fair value. Transaction costs arising on the issue of equity instruments are recognised directly in equity.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any minority interest. The excess of the cost of acquisition over the fair value of the Group's share of the identifiable net assets acquired is recorded as goodwill (refer to note 1(q)). If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directly in the income statement, but only after a reassessment of the identification and measurement of the net assets acquired.

Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions.

### (j) Impairment of assets

Assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstance indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash generating units).

### (k) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. The amount of significant cash and cash equivalents not available for use is disclosed in the note 9.

### (I) Trade Receivables

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost, less provision for doubtful debts. Trade receivables are due for settlement no more than 30 days from date of recognition. Collectibility of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for doubtful receivables is established when there is objective evidence that the Group will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. The amount of the provision is recognised in the income statement.

### (m) Investments and other financial assets

#### From 1 July 2004 to June 2005

The Group has taken the exemption available under AASB 1 to apply AASB 132 and AASB 139 only from 1 July 2005. The Group has applied previous AGAAP to the comparative information on financial instruments within the scope of AASB 132 and AASB 139.

#### From 1 July 2005

The Group classifies its investments in the following categories: financial assets at fair value through profit or loss, loans and receivables, held-to-maturity investments, and available-for-sale financial assets. The classification depends on the purpose for which the investments were acquired. Management determines the classification of its investments at initial recognition and reevaluates this designation at each reporting date.

#### (i) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise when the Group provides money, goods or services directly to a debtor with no intention of selling the receivable. They are included in current assets, except for those with maturities greater than 12 months after balance sheet date, which are classified as non-current assets. Loans and receivables are included in receivables in the balance sheet (notes 10 and 11).

### (n) Fair Value Estimation

The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or disclosure purposes.

The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.

### (o) Property, Plant and Equipment

Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Cost may also include transfers from equity of any gains/losses on qualifying cash flow hedges of foreign currency purchases of property, plant and equipment.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of the residual values, over their estimated useful lives. The expected useful lives are 2 to 10 years.

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount (note 1 (j)).

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These are included in the income statement. When revalued assets are sold, it is Group policy to transfer the amounts included in other reserves in respect of those assets to retained earnings.

### (p) Leasehold improvements

The cost of improvements to or on leasehold properties is amortised over the unexpired period of the lease or the estimated useful life of the improvement to the consolidated entity between 5 to 6 years, whichever is shorter.

### (q) Intangible Assets

#### (i) Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of the Group's share of the net identifiable assets of the acquired subsidiary/associate at the date of acquisition. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill on acquisitions of associates is included in investments in associates. Goodwill acquired in business combinations is not amortised. Instead, goodwill is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold.

Goodwill is allocated to cash-generating units for the purpose of impairment testing. Each of those cash-generating units represents the Group's investment in each company.

#### (ii) Patents and licences

Costs associated with patents are charged to the income statement in the periods in which they are incurred. Licences and acquired patents with a finite useful life are carried at cost less accumulated amortisation and impaired losses. Amortisation is calculated using the straight-line method to allocate the cost of licences and patents over the period of the expected benefit, which varies from 8 to 12 years.

#### (iii) Research and development

Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognised in the income statement as an expense when it is incurred.

Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalised if the product or service is technically and commercially feasible and adequate resources are available to complete development. The expenditure capitalised comprises all directly attributable costs, including costs of materials, services, direct labour and an appropriate proportion of overheads. Other development expenditure is recognised in the income statement as an expense as incurred. To date no development costs have been capitalised.

#### (r) Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of the reporting date which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition.

#### (s) Borrowings

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in the income statement over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

#### (t) Provisions

Provisions for legal claims are recognised when the Group has a present legal or constructive obligation as a result of past events when it is more probable than not that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are not recognised for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item in the same class of obligations may be small.

Provisions are measured at the present value of management's best estimate for the expenditure required to settle the present obligation at the balance date. The discount rate used to determine the present value reflects current market assessment at the time, value of money, and the risks specific to liability. The increase of the provision due to the passage of time is recognised as interest expense.

### (u) Employee benefits

#### (i) Wages and salaries and annual leave

Liabilities for wages and salaries, including non-monetary benefits and annual leave expected to be settled within 12 months of the reporting date are recognised in payables in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

#### (ii) Long service leave

The liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

### (iii) Superannuation

Group companies make the statutory superannuation guarantee contribution in respect of each employee to their nominated complying superannuation fund. In certain circumstances pursuant to an employee's employment contract the group companies may also be required to make additional superannuation contributions and/or agree to make salary sacrifice superannuation contributions in addition to the statutory guarantee contribution. The Group's legal or constructive obligation is limited to the above contributions.

Contributions to the employees' superannuation plans are recognised as an expense as they become payable. Prepaid contributions are recognised as an asset to the extent that a cash refund or reduction in future payments is available.

#### (iv) Employee benefits on-costs

Employee benefit on-costs, including payroll tax, are recognised and included in other liabilities and costs when the employee benefits to which they relate are recognised as liabilities.

#### (v) Share-based payments

Share-based compensation benefits are offered to the directors and employees via the Starpharma Holdings Limited Employee Share Option Plan ("SPLAM").

### Share options granted before 7 November 2002 and/or vested before 1 January 2005 No expense is recognised in respect of these options. The

shares are recognised when the options are exercised and the proceeds received allocated to share capital.

# Share options granted after 7 November 2002 and vested after 1 January 2005

The fair value of options granted under SPLAM is recognised as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which the employees become unconditionally entitled to the options.

The fair value at grant date is determined using a Black-Scholes option model that takes into account the exercise price, the term of the option, the vesting and performance criteria, the impact of dilution, the non-tradeable nature of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.

The fair value of the options granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. At each balance sheet date, the entity revises its estimate of the number of options that are expected to become exercisable. The employee benefit expense recognised in each period takes into account the most recent estimate.

#### (vi) Bonus payments

The Group recognises a liability and an expense for bonuses based on a formula that takes into consideration performance criteria that has been set. The group recognises a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

### (v) Contributed equity

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Incremental costs directly attributable to the issue of new shares or options, for the acquisition of a business, are not included in the cost of the acquisition as part of the purchase consideration.

### (w) Dividends

Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the entity, on or before the end of the period but not distributed at balance date.

### (x) Earnings per share

### (i) Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year.

### (ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

### (y) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the balance sheet.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flow.

# (z) New accounting standards and UIG interpretations

Certain new accounting standards and UIG interpretations have been published that are not mandatory for 30 June 2006 reporting periods. The Group's assessment of the impact of these new standards and interpretations is only relevant to the below:

#### (i) UIG 4 Determining whether an Asset Contains a Lease

UIG 4 is applicable to annual periods beginning on or after 1 January 2006. The Group has not elected to adopt UIG 4 early. It will apply UIG 4 in its 2007 financial statements and the UIG 4 transition provisions. The Group will therefore apply UIG 4 on the basis of facts and circumstances that existed as of 1 July 2006. Implementation of UIG 4 is not expected to change the accounting for any of the Group's current arrangements.

### 2. Financial risk management

The Group's activities expose it to a variety of financial risks; market risk (including currency risk, fair value, interest rate risk and price risk), credit risk, liquidity risk and cash flow interest rate risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. The chief executive officer and company secretary, under the guidance of the board, have responsibility for the risk management program.

### (a) Market risk

Foreign exchange risk arises when future commercial transactions and recognised assets and liabilities are denominated in a currency that is not the entity's functional currency. The Group operates internationally and is exposed to foreign exchange risk arising from currency exposures to major currencies including the US dollar. On the basis of the nature of these transactions, the Group does not consider that any potential foreign exchange exposure is material and as a consequence does not use derivative financial instruments to hedge such exposures.

### (b) Credit risk

The Group has no significant concentrations of credit risk as it does not have significant third party receivables other than under government funded research and development programs.

### (c) Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and marketable securities. The directors regularly monitor the cash position of the consolidated entity, giving consideration to the level of expenditure and future capital commitments entered into.

### (d) Cash flow interest rate risk

As the company has interest-bearing assets, the company's income and operating cash flows are subject to changes in market interest rates. The company uses fixed rate term deposits with maturities of no greater than three months.

### 3. Critical accounting estimates and judgments

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

### (a) Critical accounting estimates and assumptions

The group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

### i) Amortisation of finite life intangible assets

The Group's management determines the estimated life of the patents underlying the core technology of the business and calculates amortisation accordingly. The estimate is based on the period of expected benefit which currently stands at 8–12 years. This could change as a result of technical innovations or competitor actions in response to severe industry cycles. Management will increase amortisation charges when the useful lives are less than previously estimated lives. The carrying value of intangible assets at 30 June 2006 is \$4,086,538 (2005: nil).

*ii) Fair value of intellectual property in associate company* Prior to the application of the equity method of accounting to the results of associated entities, management will consider the underlying assets, liabilities and performance of the associated entity under the requirements of AIFRS. The appropriate fair valuation of Intellectual Property within US based associate Dendritic Nanotechnologies (DNT) has been determined using valuation techniques. The Group uses its judgment to select methods and make assumptions based on conditions existing at each balance sheet date. The Group has used a discounted cash flow analysis based on the royalties derived from the Intellectual Property to support the fair value of the asset.

# (b) Critical accounting judgments in applying accounting policies

The Group follows the guidance of AASB 136 on determining when an investment is other-than-temporarily impaired. This determination requires significant judgment. In making these judgments, the Group evaluates, among other factors, the duration and extent to which the fair value of an investment is less than its cost and the financial health of the near-term business outlook for the investee. This includes factors such as industry performance, changes in technology, operating and financing cash flow and recent transactions involving equity instruments.

### 4. Segment information

A change in accounting policy has been adopted for segment reporting to be consistent with the Group's stated goal of discovery, development and commercialisation of dendrimers for pharmaceuticals and other life science applications.

It is the view of the Directors that the risks and returns associated with each of the previous segments is substantially similar to one another. The previous segments do not reflect the Group's current strategies, including combining disease indications within the one development program. Hence, the nature of the change is the combining of all of the previous segments of virology, angiogenesis, other pharmaceuticals, dendritic nanotechnologies and unallocated into the one segment.

The disclosure impact is that no additional information is provided by segment reporting. The change in policy has no financial impact on the Group.

The consolidated entity operates in Australia, with the exception of the associated entity DNT Inc., which operates in the USA. The investment is accounted for by the equity method. The carrying value of the investment in DNT, the aggregate of losses and contribution to net profit/(loss) are outlined in note 31.

### 5. Revenue

	Consolidated		Pa	arent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Revenue from continuing operations				
Interest revenue	571,337	616,043	526,606	587,907
Other revenue	500	23,411	-	13,772
Total revenue	571,837	639,454	526,606	601,679
Other Income				
Government grants	6,422,066	1,409,844	-	_
Total other income	6,422,066	1,409,844	-	_
Total revenue and other income	6,993,903	2,049,298	526,606	601,679

### 6. Other income

	C	onsolidated	
	2006 \$	2005 \$	
Other income from government grants			
USA Government NIH contract	4,372,797	-	
USA Government NIH grant	1,495,266	1,409,844	
Australian Government P3 grant	554,003	_	
Total Government grants	6,422,066	1,409,844	

With the exception of normal audit requirements, there are no unfulfilled conditions or other contingencies attached to the portions of Government grant and contract incomes recognized above. The Group did not benefit from any other form of government assistance.

7. Expenses	0	Consolidated	Parent Entity		
	2006 \$	2005 \$	2006 \$	2005 \$	
Loss from ordinary actvities before income tax expense includes the following items:					
Depreciation	434,596	629,865	_	_	
Amortisation	530,736	64,000	287,342	_	
Rental expense	385,495	353,004	_	_	

### 8. Income tax expense

	Co	Consolidated		rent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
a) Income tax expense				
Current Tax	-	-	-	-
Deferred Tax	-	-	-	-
Under (over) provision in prior years	-	-	-	-
	-	-	-	-

Loss from continuing operations before income tax	(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Tax at the Australian tax rate of 30%		· · · · /		
	(2,256,837)	(2,324,337)	(2,852,177)	(2,228,664)
Tax effect of amounts which are not deductible (taxable) in calculating taxable income				
Amortisation of intangibles	86,203	-	86,203	-
Professional and legal fees	(42,941)	-	(42,941)	-
Research and development allowance	-	(284,579)	-	-
Equity accounted loss	209,217	100,451	-	-
Write down in carrying value of investments	-	42,000	48,000	-
Gain in dilution of equity investments	(16,670)	(370,663)	-	-
Write down in carrying value of loans	-	-	2,350,900	2,073,722
Share-based payments	60,967	48,539	-	-
Sundry items	62,068	2,889	72,992	-
Future income tax benefits not brought to account	1,897,993	2,785,700	337,023	154,942
Income tax expense	-	-	-	-
c) Amounts recognised directly in equity				
There are no amounts recognised directly in equity.				
d) Tax losses				
Unused tax losses for which no deferred tax asset has been recognised (as recovery is currently not probable)	38,124,998	34,586,777	2,124,498	644.707

(as recovery is currently not probable) 38,1	<b>124,998</b> 34,586,777	2,124,498	644,707
Potential tax benefit at 30% 11,4	<b>437,499</b> 10,376,033	637,349	193,412

Potential future income tax benefits attributable to tax losses carried forward have not been brought to account at 30 June 2006 because the directors do not believe that it is appropriate to regard the realisation of future income tax benefit as probable. Similarly, future benefits attributable to net temporary differences have not been brought to account as the directors do not regard the realisation of such benefits as probable.

### 8. Income tax expense (continued)

	Consolidated		Parent Entity	
	2006 \$	2005 \$	2006 \$	2005 \$
e) Unrecognised temporary differences				
Unrecognised temporary differences for which deferred tax assets have not been recognised	519,072	406,575	129,548	19,380
Unrecognised temporary differences for which deferred liabilities have not been recognised	(35,392)	(7,453)	(6,674)	(7,135)

### 9. Current assets - Cash and cash equivalents

	Consolidated		F	Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Cash at bank and on hand	1,500,259	2,042,795	79,012	199,060
Deposits at call	12,783,565	6,123,464	12,282,122	6,123,464
	14,283,824	8,166,259	12,361,134	6,322,524

	Consolidated		Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$		
Balance per statement of cash flows	14,283,824	8,166,259	12,361,134	6,322,524		

### Cash at bank and on hand

The cash is bearing floating interest rates based on current bank rates.

### **Deposits at call**

The deposits are bearing floating interest rates ranging from 5.00% to 5.86% (2005: 5.58%). These deposits are of 30–90 day maturities.

### **Cash not available**

There is \$481,879 of cash not available for use due to restrictions associated with a finance lease which is guaranteed by term deposit (2005: nil).

### 10. Current assets – Trade and other receivables

	Consolidated		Pa	rent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Grant receivable	2,628,146	_	-	_
Interest receivable	29,054	42,851	22,247	23,784
Prepayments	160,445	144,805	72,045	48,003
Other receivables	6,622	-	_	19,300
	2,824,267	187,656	94,292	91,087

### 10. Current assets - Trade and other receivables (continued)

#### **Grant receivables**

Grant receivables comprise expenditure reimbursable under grants from NIH and P3 are subject to normal terms of settlement within 30 to 90 days.

#### **Other receivables**

Other receivables comprise sundry debtors and GST claimable and are subject to normal terms of settlement within 30 to 90 days.

### 11. Non-current assets - Receivables

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Loans to controlled entities	_	_	26,806,901	18,970,569
Provision for doubtful debts	-	_	(26,806,901)	(18,970,569)
	_	_	-	_

#### Interest rate risk

Current and non-current receivables are non-interest bearing.

#### **Credit risk**

The Group considers that there is no concentration of credit risk with respect to current and non-current receivables. Grant receivables are with government bodies. Loans to controlled entities are assessed for recoverability and provisions are applied as considered appropriate.

### 12. Non-current assets - Investments accounted for using the equity method

		Consolidated			Parent Entity
	Notes	2006 \$	2005 \$	2006 \$	2005 \$
Shares in associated entities	31	2,387,312	2,913,061	-	-

#### **Shares in associates**

Investments in associates are accounted for in the consolidated financial statements using the equity method of accounting and carried at carrying value by the parent entity (refer to note 31).

		(	Consolidated
	Notes	2006 \$	2005 \$
Movements in the carrying amounts of investments in associates			
Carrying amount at the beginning of the financial year		2,913,061	692,194
Acquisition of investment in associates		-	1,500,699
Gain (loss) on issue of equity by associate		55,566	1,235,542
Share of losses from ordinary activities after tax		(697,390)	(334,835)
Foreign currency reserve	24	116,075	(40,539)
Write-down of investment in associate		_	(140,000)
Carrying amount at the end of the financial year		2,387,312	2,913,061

### 13. Non-current assets - Other financial assets

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Other non-traded investments				
Shares in controlled entities – at cost	_	_	17,500,106	17,500,106
Provision for diminution in value	-	_	(17,500,106)	(17,500,106)
Shares in associated entities	_	_	5,208,750	5,368,747
	_	_	5,208,750	5,368,747

At 30 June 2006 and 2005, the directors undertook to assess the recoverable amount of the parent entity's investments in its subsidiaries. Each subsidiary has a value which is directly linked to the potential cash flows which may be derived from the outcome of their respective research and development activities. At 30 June 2006 and 2005, the directors have assessed that there is not sufficient certainty with respect to those potential future cash flows to warrant the deferral of research and development expenditure (the recovery of which is not assured beyond reasonable doubt) and similarly, to support the carrying value of the parent entity's investments in its subsidiaries. As a result the carrying value of the parent entity's investments in its subsidiaries has been written down to nil as at 30 June 2006 and 2005.

### 14. Non-current assets – Property, plant and equipment

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Plant and equipment (at cost)	1,946,944	1,766,727	-	_
Less: Accumulated Depreciation	(1,345,639)	(1,248,823)	-	_
	601,305	517,904	-	_
Leasehold improvements (at cost)	1,135,956	1,128,512	-	_
Less: Accumulated Depreciation	(753,182)	(541,652)	-	_
	382,774	586,860	-	_
Plant and equipment under finance lease	758,072	320,000	-	_
Less: Accumulated Depreciation	(311,027)	(192,000)	-	_
	447,045	128,000	-	_
	1,431,124	1,232,764	-	-

### **Reconciliations of carrying amounts**

Consolidated	Plant and Equipment	Leasehold improvements	Plant and Equipment under finance lease
	2006 \$	2006 \$	2006 \$
Year ended 30 June 2006			
Opening amount at 1 July 2005	517,904	586,860	128,000
Additions	455,740	7,444	438,072
Disposals	(24,906)	_	_
Depreciation and amortisation	(347,433)	(211,530)	(119,027)
Carrying amount at 30 June 2006	601,305	382,774	447,045

### 14. Non-current assets - Property, plant and equipment (continued)

Consolidated	Plant and Equipment	Leasehold improvements	Plant and Equipment under finance lease
	2005 \$	2005 \$	2005 \$
Year ended 30 June 2005			
Opening amount at 1 July 2004	596,798	767,467	192,000
Additions	363,164	7,200	_
Disposals	_	_	_
Depreciation and amortisation	(442,058)	(187,807)	(64,000)
Carrying amount at 30 June 2005	517,904	586,860	128,000

### 15. Non-current assets - Intangible assets

	Consolidated		Parent Entit	
	2006 \$	2005 \$	2006 \$	2005 \$
Patents and Licences	4,373,880	_	4,373,880	
Less: Accumulated amortisation	(287,342)	_	(287,342)	
Net book value	4,086,538	-	4,086,538	-
Opening amount at 1 July		_	-	
Additions	4,373,880	_	4,373,880	_
Amortisation charge	(287,342)	_	(287,342)	_
Carrying amount at 30 June	4,086,538	-	4,086,538	-

Starpharma acquired outright ownership of its core technology including the patents underlying the VivaGel<sup>™</sup> family of products and the 25% royalty that was payable to BRI under the original licence was cancelled. The ownership rights were acquired through the issue of Starpharma shares to BRI.

The value of the shares issued, measured at the published market price on the date of the agreement, was recorded to the balance sheet as an intangible asset. To the year end amortisation of \$287,342 has been recorded to the income statement reducing the carrying value of the intangible asset to \$4,086,538.

### 16. Current liabilities - Trade and other payables

	Consolidated		Parent Entity	
	2006 \$	2005 \$	2006 \$	2005 \$
Trade creditors	1,897,819	1,647,182	830,499	111,622
Loans from controlled entities	-	_	653,655	653,654
	1,897,819	1,647,182	1,484,154	765,276

### 17. Current liabilities - Borrowings

	(	Consolidated		Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Finance lease liability (secured)	142,092	60,007	-	-

Details of the security relating to each of the secured liabilities are set out in Note 20.

### 18. Current liabilities - Provisions

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Employee entitlements	331,447	279,589	-	_

### 19. Current liabilities - Deferred Income

	Consolidated		Parent Ent	
	2006 \$	2005 \$	2006 \$	2005 \$
Deferred grant income	661,337	378,063	-	-

### 20. Non-current liabilities - Borrowings

	Consolidated		Parent En	
	2006 \$	2005 \$	2006 \$	2005 \$
Finance lease liability (secured)	315,412	79,750	-	_

Lease liabilities are effectively secured as the rights to the leased assets recognised in the financial statements revert to the lessor in the event of default.

Floating Interest rate Fixed interest r				rest rate				
2006		1 year or less	Over 1–2 years	Over 2–3 years	Over 3–4 years	Over 4–5 years	Over 5 years	Total
Lease Liabilities (notes 17, 20 and 29)	_	142,092	68,979	73,844	79,052	93,537	_	457,504
Weighed average interest	rate –	6.72%	7.20%	7.20%	7.20%	7.20%	_	

_					Fixed interest rate			
2005		1 year or less	Over 1–2 years	Over 2–3 years	Over 3–4 years	Over 4–5 years	Over 5 years	Total
Lease Liabilities (notes 17, 20 and 29)	_	60,007	60,007	19,743	_	_	_	139,757
Weighed average interest ra	te –	6.26%	6.26%	6.26%	_	_	_	

### 21. Non-current liabilities - Provisions

	Consolidated		Parent Entit	
	2006 \$	2005 \$	2006 \$	2005 \$
Employee entitlements	107,630	89,184	_	_

### 22. Non-current liabilities - Deferred Income

	Consolidated		Parent Enti	
	2006 \$	2005 \$	2006 \$	2005 \$
Deferred grant income (equipment purchase)	241,342	_	_	_

### 23. Contributed equity

### (a) Share Capital

	Parent Entity and Consolidated			ent Entity and Consolidated
	2006 Shares	2005 Shares	2006 \$	2005 \$
Share Capital				
Ordinary shares – fully paid	147,739,245	111,235,000	65,375,467	46,821,956
Former share premium account included in equity			2,500,000	2,500,000

### (b) Movements in ordinary share capital

Date	Details	Number of Shares	Issue Price	\$
1 July 2004	Opening Balance	111,235,000		46,821,956
10 October 2005	BRI Share Placement	7,112,000	\$0.62	4,373,880
17 November 2005	Share Placement	9,573,250	\$0.51	4,882,358
	Less: Transaction Costs			(244,118)
29 December 2005	Share Placement and Share Purchase Plan	19,818,995	\$0.51	10,107,687
	Less: Transaction Costs			(566,296)
		147,739,245		65,375,467

Under the BRI share placement, Starpharma acquired outright ownership of its core technology including the patents underlying the VivaGel<sup>™</sup> family of products and the 25% royalty that was payable to BRI under the original licence was cancelled.

### (c) Ordinary shares

As at 30 June 2006 there were 147,739,245 issued ordinary shares.

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the company in proportion to the number of and amounts paid on the shares held.

### (d) Options

Information relating to the Starpharma Holdings Limited Employee Share Option Plan, including details of options issued, exercised and expired during the financial year and options outstanding at the end of the financial year are set out in Note 36.

### 24. Reserves

### (a) Reserves

Consolidated **Parent Entity** 2006 2005 2006 2005 \$ \$ \$ \$ Share-based payments reserve 421,838 218,615 421,838 218,615 Foreign currency translation reserve 75,536 (40, 539)\_ 497,374 178,076 421,838 218,615

The value of the shares issued, measured at the published market price on the date of the agreement, was recorded to the balance sheet as an intangible asset.

On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.

### 24. Reserves (continued)

### b) Movement in reserves

	Consolidated		Parent En	
	2006 \$	2005 \$	2006 \$	2005 \$
Share-based payments reserve				
Balance 1 July	218,615	56,816	218,615	56,816
Option expense	203,223	161,799	203,223	161,799
Balance 30 June	421,838	218,615	421,838	218,615

#### Foreign currency translation reserve

Balance 1 July	(40,539)	_	-	-	
Currency translation differences arising during the year	116,075	(40,539)	_	_	
Balance 30 June	75,536	(40,539)	-	-	

#### (c) Nature and purpose of reserves

### (i) Share-base payments reserve

The share-based payments reserve is used to recognise the fair value of options issued but not exercised.

#### (ii) Foreign currency translation reserve

Exchange differences arising on translation of the foreign associated entity are taken to the foreign currency translation reserve, as described in Note 1(d). The reserve is recognised in profit and loss when the net investment is disposed of.

### 25. Accumulated Losses

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Accumulated losses balance 1 July	(37,034,067)	(29,286,276)	(36,023,489)	(28,594,609)
Net loss for the year	(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Accumulated losses balance 30 June	(44,556,855)	(37,034,067)	(45,530,745)	(36,023,489)

### 26. Key management personnel disclosures

### (a) Directors

The following persons were directors of Starpharma Holdings Limited during the financial year:

Name	Position
PT Bartels	Chairman – non executive
J W Raff	Executive director, Chief Executive Officer
P M Colman	Non-executive director
R Dobinson	Non-executive director
L Gorr	Non-executive director
P J Jenkins	Non-executive director

J W Raff retired from the position of Chief Executive Officer on 1 July 2006. He will remain a non-executive director and was appointed Deputy Chairman.

J K Fairley was appointed to the position of Chief Executive Officer and Executive director on 1 July 2006.

#### (b) Other key management personnel

The following persons also had authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, during the financial year:

Name	Position
J K Fairley	Chief Operating Officer (from 4 July 2005)
B P Rogers	Company Secretary and Chief Financial Officer
O T Grogan	VP – Commercial Development & Licensing
T D McCarthy	VP – Drug Development
G Y Krippner	Head of Chemistry
J R Paull	VP – Regulatory and Clinical Affairs
C P Barrett	VP – Business Development (from 18 July 2005)
N J Baade	Financial Controller (from 16 January 2006)

#### Key management personnel during the year ended 30 June 2005 were:

Name	Position
B P Rogers	Company Secretary and Chief Financial Officer
O T Grogan	VP – Commercial Development & Licensing
A Szabo	VP – Business Development (ceased employment 31 January 2005)
T D McCarthy	VP – Drug Development
G Y Krippner	Head of Chemistry
J R Paull	VP – Regulatory and Clinical Affairs

#### (c) Key management personnel compensation

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Short-term employee benefits	1,684,432	1,229,432	519,011	497,615
Post-employment benefits	365,707	271,547	186,124	182,259
Share-based payments	153,340	135,422	-	_
	2,203,479	1,636,401	705,135	679,874

The company has taken advantage of the relief provided by ASIC Class Order 06/50 and has transferred the detailed remuneration disclosures to the directors' report. The relevant information can be found in sections A-C of the remuneration report on pages 25 to 29.

#### (d) Equity instrument disclosures relating to key management personnel

#### Options provided as remuneration and shares issued on exercise of such options

Details of options provided as remuneration and shares issued on the exercise of such options, together with terms and conditions of the options, can be found in section D of the remuneration report on pages 29 to 31.

#### **Option holdings**

The numbers of options over ordinary shares in the company held during the financial year by each director of Starpharma Holdings Limited and other key management personnel of the Group, including their personally related parties, are set out below. No options are held by Directors in either the current or prior year.

#### 2006

Name	Balance at the start of the year	Granted during the year as compensation	Exercised during the year	Other changes during the year	Balance at the end of the year	Vested and exercisable at the end of the year
Other key manag	gement personnel of the	e Group				
J K Fairley	_	300,000	_	_	300,000	_
O T Grogan	300,000	-	_	(100,000)	200,000	100,000
B P Rogers	220,000	-	_	_	220,000	220,000
T D McCarthy	220,000	-	_	(20,000)	200,000	200,000
G Y Krippner	200,000	-	_	_	200,000	200,000
J R Paull	100,000	-	_	_	100,000	100,000
C P Barrett	_	100,000	_	_	100,000	_
N J Baade	_	-	-	-	-	_

#### 2005

Name	Balance at the start of the year	Granted during the year as compensation	Exercised during the year	Other changes during the year	Balance at the end of the year	Vested and exercisable at the end of the year
Other key manag	ement personnel of the	e Group				
O T Grogan	200,000	100,000	_	_	300,000	200,000
B P Rogers	220,000	_	_	_	220,000	_
A Szabo	5,000	100,000	_	(105,000)	_	_
T D McCarthy	220,000	_	_	_	220,000	120,000
G Y Krippner	200,000	_	_	_	200,000	_
J R Paull	100,000	_	_	_	100,000	20,000

### Share holdings

The numbers of ordinary shares in the company held during the financial year by each director of Starpharma Holdings Limited and other key management personnel of the Group, including their personally related parties, are set out below. There were no shares granted during the reporting period as compensation.

2006	Balance at the	Received during the year	Other changes	Balance at the
Name	start of the year	on the exercise of options	during the year	end of the year
Directors of Starphar	ma Holdings Limited			
Ordinary Shares				
P T Bartels	100,000		9,804	109,804
P M Colman	5,982,482		9,804	5,992,286
R Dobinson	3,155,976	_	(250,000)	2,905,976
L Gorr	5,194,900	-	9,804	5,204,704
P J Jenkins	1,606,000	-	29,608	1,635,608
J W Raff	5,362,081	-	19,608	5,381,689
Other key manageme	ent personnel of the Group			
Ordinary Shares				
J K Fairley	5,000	_	_	5,000
O T Grogan	-	-	_	-
B P Rogers	61,700	_	3,922	65,622
T D McCarthy	4,000	-	_	4,000
G Y Krippner	-	-	_	
J R Paull	_	_	_	_
C P Barrett	_	-	8,935	8,935
N J Baade	_	_	_	_
2005				
Name	Balance at the start of the year	Received during the year on the exercise of options	Other changes during the year	Balance at the end of the year
Directors of Starphar	ma Holdings Limited			
Ordinary Shares				
P T Bartels	80,000	_	20,000	100,000
P M Colman	5,982,482	-	_	5,982,482
R Dobinson	3,505,976	_	(350,000)	3,155,976
L Gorr	5,560,500	-	(365,600)	5,194,900
P J Jenkins <sup>1</sup>	1,654,000	_	(48,000)	1,606,000
J W Raff <sup>1</sup>	5,322,081	-	40,000	5,362,081
Other key manageme	ent personnel of the Group			
Ordinary Shares				
O T Grogan <sup>1</sup>	_	_	_	_
B P Rogers	41,700	_	20,000	61,700
A Szabo	_	-	_	
	1 000		_	4,000
T D McCarthy	4,000			
T D McCarthy G Y Krippner	4,000		_	_

<sup>1</sup>A difference from 2005 disclosures is due to a change in definition under AASB 124 *Related Party Disclosures*.

#### (e) Other transactions with key management personnel

A director, Mr L Gorr is a partner of the firm, Herbert Geer & Rundle, which rendered legal services to the consolidated entity. All such dealings with the consolidated entity were in the ordinary course of business and on normal terms and conditions.

Aggregate amounts of each of the above types of other transactions with key management personnel of Starpharma Holdings Limited and the Group.

	Consolidated		Pare	
	2006 \$	2005 \$	2006 \$	2005 \$
Amounts recognised as expense				
Legal fees	_	1,901	_	_

Apart from the above no director has entered into a material contract with the consolidated entity since the end of the previous financial year and there were no material contracts involving directors' interests subsisting at year end.

### 27. Remuneration of auditors

The Company may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the Company and/or the consolidated entity are important.

Details of the amounts paid or payable to the auditor (PricewaterhouseCoopers) for audit and non-audit services provided during the year are set out below.

During the year the following fees were paid or payable for services provided by the auditor (PricewaterhouseCoopers) of the parent entity, its related practices and non-related audit firms:

	Consolidated		Pa	rent Entity	
	2006 \$	2005 \$	2006 \$	2005 \$	
Assurance Services					
Audit or review of financial reports of the entity or any entity in the consolidated entity under the <i>Corporations Act 2001</i>	114,990	92,500	114,990	92,500	
Other assurance services:- Grant reviews and program audits	7,500	22,000	7,500	22,000	
	122,490	114,500	122,490	114,500	

No Taxation or Advisory Services were provided in the current or previous year.

### 28. Contingencies

The Company has no contingent liabilities.

### 29. Commitments

### (a) Capital Commitments

Capital expenditure contracted for at the reporting date but not recognised as liabilities is as follows:

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Property, plant and equipment				
Within one year	69,108	_	-	
Later than one year but not later than five years	-	_	-	
Later than five years	_	_	-	
	69,108	-	-	-

## 29. Commitments (continued)

### (b) Lease Commitments

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Commitments in relation to leases contracted for at the reporting date but not recognised as liabilities, payable:				
Not later than one year	423,681	123,293	_	_
Later than one year and not later than five years	683,283	72,695	-	_
Later than five years	_	_	-	_
	1,106,964	195,988	-	-
Representing:				
Cancellable operating leases	649,461	56,231	-	_
Non-cancellable finance lease	539,745	144,000	-	_
Future finance charges on finance leases	(82,242)	(4,243)	-	_
	1,106,964	195,988	_	-

#### **Operating leases**

The Group leases laboratory and offices under a lease until 31 August 2008 and leases various plant and equipment under cancelable operating leases.

	Consolidated		Pa	rent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Commitments for minimum lease payments in relation to cancellable operating leases are payable as follows:				
Not later than one year	287,246	51,293	_	_
Later than one year and not later than five years	362,215	4,938	_	_
Later than five years	_	-	_	_
Representing cancellable operating leases	649,461	56,231	-	_

### 29. Commitments (continued)

#### **Finance Leases**

The Group leases various plant and equipment with a carrying amount of \$457,504 (2005: \$139,757) under finance leases expiring within one to five years.

	Consolidated		F	Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Commitments in relation to finance leases are payable as follows:				
Not later than one year	161,443	72,000	_	_
Later than one year and not later than five years	378,303	72,000	-	_
Later than five years	_	_	-	_
Minimum lease payments	539,746	144,000	-	_
Future finance charges	(82,242)	(4,243)	_	
Recognised as a liability	457,504	139,757	-	-
Representing finance lease liabilities:				
Current (note 17)	142,092	60,007	-	_
Non-Current (note 20)	315,412	79,750	-	_
	457,504	139,757	_	-

The weighted average interest rates implicit in the leases range from 6.26% to 7.20% (2005: 6.26%).

#### (c) Expenditure Commitments

The Group has entered into various agreements for the research and development services. All material committed expenditure is reimbursable under existing grant funding sources.

### (d) Termination Commitments

The service contracts of key management personnel include benefits payable by the Group on termination of the employee's contract. Refer to section C of the remuneration report on pages 28 and 29 for details of these commitments.

### 30. Subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1(b).

		-	Equity	Holding		arent Entity's g Investment
Name of entity	Country of Incorporation	Class of Shares	2006 %	2005 %	2006 \$	2005 \$
Starpharma Pty. Limited	Australia	Ordinary	100%	100%	9,900,001	9,900,001
Angiostar Pty. Limited	Australia	Ordinary	100%	100%	3,300,005	3,300,005
Viralstar Pty. Limited	Australia	Ordinary	100%	100%	4,300,000	4,300,000
Preclin Pty. Limited	Australia	Ordinary	100%	100%	100	100
					17,500,106	17,500,106

### 31. Investments in associates

Investments in associates are accounted for in the consolidated financial statements using the equity method of accounting and are carried at carrying value by the parent entity. Information relating to the associates is set out below.

#### (a) Carrying amounts

			Equit	ty Holding	of Pa	rrying value rent Entity's Investment
Name of entity	Country of Incorporation	Class of Shares	2006 %	2005 %	2006 \$	2005 \$
Dendritic Nanotechnologies, Inc.	USA	Ordinary	32.91%	32.90%	5,168,747	5,168,747
Dimerix Bioscience Pty Ltd	Australia	Ordinary	22.00%	30.00%	40,003	200,000
					5,208,750	5,368,747

The value of Dimerix Bioscience Pty Ltd has been reduced from its cost base of \$200,000 to a carrying value of \$40,003. A provision for diminution of \$159,997 has been booked in the year.

#### (b) Movements in carrying amounts

	Consolidated	
	2006 \$	2005 \$
Movements in the carrying amounts of investments in associates		
Carrying amount at the beginning of the financial year	2,913,061	692,194
Acquisition of investment in associates	-	1,500,699
Gain (loss) on issue of equity by associate	55,566	1,235,542
Share of losses from ordinary activities after tax	(697,390)	(334,835)
Foreign currency reserve (note 24)	116,075	(40,539)
Write-down of investment in associate	-	(140,000)
Carrying amount at the end of the financial year	2,387,312	2,913,061

#### (c) Reserves attributable to associates

	Consolidated	
	2006 \$	2005 \$
Foreign currency reserve		
Balance at the beginning of the financial year	(40,539)	
Net exchange differences on translation of results of associated entity	116,075	(40,539)
Balance at the end of the financial year	75,536	(40,539)

### 31. Investments in associates (continued)

### (d) Summary of the performance and financial position of associates

	Consolidate	
	2006 \$	2005 \$
Dendritic Nanotechnologies, Inc.		
Profits (Loss) from ordinary activities after related income tax expenses	(1,877,870)	(785,278)
Assets	7,395,480	8,927,661
Liabilities	264,218	247,219
Dimerix Bioscience Pty Ltd		
Profits (Loss) from ordinary activities after related income tax expenses	(347,206)	(49,980)
Assets	507,758	151,357
Liabilities	104,943	1,337

### 32. Events occurring after the balance sheet date

Dr Jacinth Fairley was appointed Chief Executive Officer and director on 1 July 2006. Dr J W Raff reverted to a non-executive director capacity and was appointed Deputy Chairman. 500,000 Employee Share Options were offered to Dr J K Fairley subject to shareholder approval at the next Annual General Meeting of the Company.

The options will be granted in accordance with the terms of the Company's Employee Share Option Plan and will include the following terms and conditions:

- Issue price: nil.
- Exercise Price: 45.08 cents per share.

(Determined on the basis of market value plus 15%. Market value is based on a 15 day volume weighted average price of the Company's shares prior to 1 July 2006, the date of appointment of the Executive to the position of CEO.)

- Exercise period: From 1st July 2007 to 30 June 2009.

There are no other significant events occurring since 30 June 2006 that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group.

### 33. Reconciliation of profit after income tax to net cash inflow from operating activities

	Consolidated			Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Operating loss after tax:	(7,522,789)	(7,747,791)	(9,507,256)	(7,428,880)
Depreciation and amortisation	965,333	693,865	287,342	_
Non-cash employee benefits -share-based payments	203,223	161,799	_	_
Change in operating assets and liabilities, net of effects of acquisitions and disposals of entities:				
(Increase) decrease in receivables and other assets	(2,602,581)	141,980	(3,208)	33,481
Increase (decrease) in trade creditors	250,637	1,204,445	718,877	(16,648)
Increase in employee provisions	70,304	119,758	_	_
Increase in deferred income	524,616	378,063	_	_
Share in results of associates	641,825	(760,708)	_	_
Gain on sale of property, plant and equipment	(20,516)	_	_	_
Provision for doubtful debts	_	_	7,996,332	6,912,407
Net cash outflows from operating activities	(7,489,948)	(5,808,589)	(507,913)	(499,640)

### 34. Non-cash financing activities

	Consolidated		F	Parent Entity
	2006 \$	2005 \$	2006 \$	2005 \$
Acquisition of property, plant and equipment by means of finance lease	438,000	_	_	_
Outright acquisition of IP by means of share issue	4,373,880	-	4,373,880	_

### 35. Earnings per share

	Consolidated	
	2006 Cents	2005 Cents
Basic loss per share	(5.69)	(6.97)
Diluted loss per share	(5.69)	(6.97)
Net loss attributable to members of Starpharma Holdings Limited used as the numerator in calculating diluted and basic earnings per share	(7,522,789)	(7,747,791)
Weighted average number of ordinary shares outstanding during the year used as the denominator in calculating diluted and basic earnings per share	132,297,514	111,235,000

### 36. Share-based payments

### (a) Employee Option Plan

The establishment of the Starpharma Holdings Limited Employee Share Option Plan was approved by shareholders at the Annual General Meeting held on 17 November 2004. All full-time or part-time employees and directors of the Company or associated companies are eligible to participate in the Plan.

The objective of the Plan is to assist in the recruitment, reward, retention and motivation of employees of the Company.

Options are granted under the plan for no consideration.

#### 2006

Options are normally granted for a four or five year period and become exercisable on the second anniversary of the date of grant.

Options granted under the plan carry no dividend or voting rights.

Each option is personal to the participant and is not transferable, transmissible, assignable or chargeable, except with the written consent of the remuneration and nomination committee.

Set out below are summaries of options granted under the plan:

Grant Date	Expiry Date	Exercise Price	Balance at start of the year	Granted during the year	Forfeited during the year	Expired during the year	Balance at end of the year	Exercisable at end of the year
			Number	Number	Number	Number	Number	Number
Consolidated	and parent entity	/						
7 Feb 2001	31 Dec 2005	93.75 cents	220,000	-	_	220,000	-	_
12 Apr 2002	11 Apr 2007	93.75 cents	220,000	_	_	_	220,000	220,000
21 Jun 2002	30 Jun 2007	93.75 cents	200,000	-	_	_	200,000	200,000
6 Feb 2004	31 Dec 2008	73.00 cents	200,000	_	_	_	200,000	200,000
8 Feb 2004	8 Feb 2009	93.75 cents	730,000	_	10,000	_	720,000	720,000
31 Dec 2004	31 Dec 2009	93.75 cents	182,000	_	15,000	_	167,000	_
12 May 2005	12 May 2010	93.75 cents	100,000	_	_	_	100,000	_
4 Jul 2005	4 Jul 2010	93.75 cents	_	300,000	_	_	300,000	_
18 Jul 2005	18 Jul 2010	93.75 cents	_	100,000	_	_	100,000	_
Total			1,852,000	400,000	25,000	220,000	2,007,000	1,340,000
Weighted average exercise price			91.51 cents	93.75 cents	93.75 cents	93.75 cents	91.68 cents	90.65 cents

No options were exercised during the year.

2005

Grant Date	Expiry Date	Exercise Price	Balance at start of year	Granted during the year	Forfeited during the year	Expired during the year	Balance at end of the year	Exercisable at end of the year	
			Number	Number	Number	Number	Number	Number	
Consolidated and parent entity									
7 Feb 2001	31 Dec 2005	93.75 cents	240,000	_	20,000	_	220,000	220,000	
12 Apr 2002	11 Apr 2007	93.75 cents	220,000	_	_	_	220,000	220,000	
21 Jun 2002	30 Jun 2007	93.75 cents	200,000	_	_	-	200,000	200,000	
6 Feb 2004	31 Dec 2008	73.00 cents	200,000	_	_	_	200,000	200,000	
8 Feb 2004	8 Feb 2009	93.75 cents	749,000	_	19,000	_	730,000	_	
1 Jul 2004	1 Jul 2009	93.75 cents	_	100,000	100,000	_	_	_	
31 Dec 2004	31 Dec 2009	93.75 cents	_	182,000	_	_	182,000	_	
12 May 2005	12 May 2010	93.75 cents	_	100,000	_	_	100,000	_	
Total			1,609,000	382,000	139,000	-	1,852,000	840,000	
Weighted average exercise price			91.17 cents	93.75 cents	93.75 cents	_ cents	91.51 cents	88.81 cents	

No options were exercised during the year.

### 36. Share-based payments (continued)

The weighted average remaining contractual life of share options outstanding at the end of the period was 2.65 years (2005: 2.99 years).

#### Fair value of options granted

The weighted average assessed fair value at grant date of options granted during the year ended 30 June 2006 was \$0.15 per option (2005: \$0.33). The fair value at grant date is independently determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and the expected price volatility of the underlying share, the expected dividend yield and the risk free rate for the term of the option.

The expected price volatility is based on the historic volatility (based on the remaining life of the options), adjusted for any expected changes to future volatility due to publicly available information.

Options are granted for no consideration, have a four or five year life and become exercisable on the second anniversary of the date of grant.

Options granted during the year ended 30 June 2006 were:

Options granted on:	4 July 2005	18 July 2005
Number of options granted	300,000	100,000
Expiry date	4 July 2010	18 July 2010
Exercise price	93.75 cents	93.75 cents
Expected price volatility of the company's shares	46.9%	46.9%
Risk-free interest rate	5.2%	5.2%
Expected dividend yield	-	_
Share price at grant date	50 cents	52 cents
Assessed fair value	14.56 cents	15.74 cents

Options granted during the year ended 30 June 2005 were:

Options granted on:	1 July 2004	31 Dec 2004	12 May 2005
Number of options granted	100,000	192,000	100,000
Expiry date	1 July 2009	31 Dec 2009	12 May 2010
Exercise price	93.75 cents	93.75 cents	93.75 cents
Expected price volatility of the company's shares	75.0%	47.6%	46.9%
Risk-free interest rate	5.9%	5.3%	5.7%
Expected dividend yield	_	_	_
Share price at grant date	74 cents	74 cents	66 cents
Assessed fair value	45.00 cents	30.52 cents	25.33 cents

#### (b) Expenses arising from share-based payment transactions

Total expenses arising from share-based payment transactions recognised during the period as part of employee benefit expense were as follows:

	C	onsolidated	Parent Entity	
	2006 \$	2005 \$	2006 \$	2005 \$
Options issued under employee option plan	203,223	161,799	_	-

### 37. Related Party Transactions

#### (a) Parent entity and subsidiaries

The parent entity of the Group is Starpharma Holdings Limited. Interests in subsidiaries are set out in note 30.

#### (b) Key management personnel

Disclosures relating to key management personnel are set out in note 26.

#### (c) Transactions with related parties

The following transactions occurred with related parties:

	Consolidated		Parent Entity		
	2006 \$	2005 \$	2006 \$	2005 \$	
Other Transactions					
Funds advanced to subsidiary	-	_	7,683,238	6,750,600	
Funds advanced from subsidiary	-	_	(50,129)	(259,290)	
Share-based payments	-	_	203,223	161,790	
Management services to parent	-	_	(640,467)	_	

All transactions were made on normal commercial terms and conditions and at market rates, except that there are no fixed terms for the repayment of outstanding balances.

#### (d) Outstanding balances arising from sales/ purchases of goods and services

	Co	Consolidated		Parent Entity	
	2006 \$	2005 \$	2006 \$	2005 \$	
Current Receivables					
Management services to parent	-	_	704,514	-	

Outstanding balances are payable in cash.

## 38. Explanation of transition to Australian equivalents to IFRSs

#### 1 Reconciliation of equity reported under previous Australian Generally Accepted Accounting Principles (AGAAP) to equity under Australian equivalents to IFRSs (AIFRS)

#### (a) At the date of transition to AIFRS: 1 July 2004

		Consolidated					Parent Entity
	Notes	Previous AGAAP	Effect of transition to AIFRS	AIFRS	Previous AGAAP	Effect of transition to AIFRS	AIFRS
-					\$	\$	\$
Current assets							
Cash and cash equivalents		15,658,300	-	15,658,300	14,524,569	_	14,524,569
Trade and other receivables		584,183	-	584,183	414,259	-	414,259
Total current assets		16,242,483	_	16,242,483	14,938,828	_	14,938,828
Non-current assets							
Property, plant and equipment		1,556,265	-	1,556,265	_	-	-
Intangible assets		_	-	-	-	-	-
Investments accounted for using the equity method		692,194	_	692,194	-	_	-
Other financial assets		_	_	-	3,868,048	_	3,868,048
Total non-current assets		2,248,459	_	2,248,459	3,868,048	_	3,868,048
Total assets		18,490,942	-	18,490,942	18,806,876	-	18,806,876
Current liabilities							
Trade and other payables		445,908	_	445,908	522,713	_	522,713
Provisions		249,015	_	249,015	-	_	_
Borrowings		60,007	_	60,007	-	_	_
Deferred Income		_	_	_	_	_	_
Total current liabilities		754,930	_	754,930	522,713	_	522,713
Non-current liabilities							
Borrowings		143,516	_	143,516	_	_	-
Provisions		-	_	-	-	_	_
Deferred Income		_	_	-	_	_	-
Total non-current liabilities		143,516	_	143,516	_	_	_
Total liabilities		898,446	-	898,446	522,713	-	522,713
Net assets		17,592,496	_	17,592,496	18,284,163	-	18,284,163
Equity		16 001 050		16 001 050	16 001 050		16 001 050
Contributed equity Share based payment reserve	28 1/h)	46,821,956	-	46,821,956	46,821,956	56 016	46,821,956
	38.4(b)	-	56,816	56,816		56,816	56,816
Foreign currency translation reserve	. ,	12,709	(12,709)	(20.286.276)	(28 537 703)	(56.016)	(28 504 600)
Accumulated losses	38.4(d)	· · ·	(44,107)	(29,286,276)	(28,537,793)	(56,816)	(28,594,609)
Total equity		17,592,496	_	17,592,496	18,284,163	_	18,284,163

## 38. Explanation of transition to Australian equivalents to IFRSs (continued)

#### (b) At the end of the last reporting period under previous AGAAP: 30 June 2005

		Consolidated					Parent Entity
	Notes	Previous AGAAP	Effect of transition to AIFRS	AIFRS	Previous AGAAP	Effect of transition to AIFRS	AIFRS
		\$	\$	\$	\$	\$	\$
Current assets							
Cash and cash equivalents		8,166,259	_	8,166,259	6,322,524	_	6,322,524
Trade and other receivables		187,656	_	187,656	91,087	-	91,087
Total current assets		8,353,915	-	8,353,915	6,413,611	-	6,413,611
Non-current assets							
Property, plant and equipment		1,232,764	_	1,232,764	_	_	_
Intangible assets		-	_	_	_	_	_
Investments accounted for using the equity method		2,913,061	_	2,913,061	_	_	_
Other financial assets		_	_	_	5,368,747	_	5,368,747
Total non-current assets		4,145,825	_	4,145,825	5,368,747	_	5,368,747
Total assets		12,499,740	-	12,499,740	11,782,358	-	11,782,358
Current liabilities							
Trade and other payables		1,647,182	_	1,647,182	765,276	_	765,276
Provisions		279,589	_	279,589	_	_	_
Borrowings		60,007	_	60,007	_	_	_
Deferred Income		378,063	_	378,063	_	_	-
Total current liabilities		2,364,841	_	2,364,841	765,276	_	765,276
Non-current liabilities							
Borrowings		79,750	_	79,750	_	-	-
Provisions		89,184	_	89,184	_	-	-
Deferred Income		_	_	_	_	_	_
Total non-current liabilities		168,934	_	168,934	-	_	_
Total liabilities		2,533,775	-	2,533,775	765,276	-	765,276
Net assets		9,965,965	-	9,965,965	11,017,082	_	11,017,082
Equity							
Contributed equity		46,821,956	_	46,821,956	46,821,956	_	46,821,956
Share based payment reserve	38.4(b)		218,615	218,615		218,615	218,615
Foreign currency translation reserve	38.4(a)	(27,830)	(12,709)	(40,539)	-	_	-
Accumulated losses	38.4(d)	(36,828,161)	(205,906)	(37,034,067)	(35,804,874)	(218,615)	(36,023,489)
Total equity		9,965,965		9,965,965	11,017,082		11,017,082

### 38. Explanation of transition to Australian equivalents to IFRSs (continued)

#### 2 Reconciliation of loss for year ended 30 June 2005

		Consolidated					Parent Entity
	Notes	Previous AGAAP	Effect of transition to AIFRS	AIFRS	Previous AGAAP	Effect of transition to AIFRS	AIFRS
		\$	\$	\$	\$	\$	\$
Revenue from continuing operations	38.4(c)	2,049,298	(1,409,844)	639,454	601,679	-	601,679
Other income	38.4(c)		1,409,844	1,409,844			
Administration expense	38.4(b)	(3,380,015)	(161,799)	(3,541,814)	(1,118,152)	_	(1,118,152)
Research and development expense		(7,007,693)	_	(7,007,693)	_	_	_
Provision for diminution		-	-	-	(6,750,608)	(161,799)	(6,912,407)
Finance costs		(8,290)	_	(8,290)	_	_	_
Share of results of associates accounted for using the equity method		760,708	_	760,708	_	_	_
Loss before income tax		(7,585,992)	(161,799)	(7,747,791)	(7,267,081)	(161,799)	(7,428,880)
Income tax expense		_	_	-	_	_	-
Loss for the year		(7,585,992)	(161,799)	(7,747,791)	(7,267,081)	(161,799)	(7,428,880)
Loss attributable minority interests		_	_	_	_	_	_
Loss attributable to members of Starpharma Holdings Limited		(7,585,992)	(161,799)	(7,747,791)	(7,267,081)	(161,799)	(7,428,880)

#### 3 Reconciliation of cash flow statement for the year ended 30 June 2005

The adoption of AIFRS has not resulted in any material adjustments to the cash flow statement.

#### 4 Notes to the reconciliations

# (a) Foreign currency translation reserve: cumulative translation differences

The Group has elected to apply the exemption in AASB 1 *First-time Adoption of Australian Equivalents* to international Financial Reporting Standards. The cumulative translation differences for all foreign operations represented in the foreign currency translation reserve are deemed to be zero at the date of transition to AIFRS. The effect is:

#### (i) At 1 July 2004

For the Group the balance of the \$12,709 credit in the foreign currency translation reserve is reduced to zero. Retained earnings is decreased by this amount. There is no effect on the parent entity.

#### (ii) At 30 June 2005

For the Group the balance of the foreign currency translation reserve is reduced by \$12,709. Retained earnings is decreased by this amount. There is no effect on the parent entity.

(iii) For the year ended 30 June 2005

There is no effect on the Group or parent entity.

#### (b) Share-based payments

Under AASB 2 *Share-based Payment* from 1 July 2004 the Group is required to recognise an expense for those options that were issued to employees under the Starpharma Holdings Limited Employee Option Plan after 7 November 2002 but that had not vested by 1 January 2005. No such expense was required to be recognised under previous AGAAP. The effect of this is:

#### (i) At 1 July 2004

For the Group there has been a decrease in retained earnings of \$56,816 and a corresponding increase in reserves. The effect is the same for the parent entity.

#### (ii) At 30 June 2005

For the Group there has been a decrease in retained earnings of \$218,615 and a corresponding increase in reserves. The effect is the same for the parent entity.

#### (iii) For the year ended 30 June 2005

For the Group there has been an increase in administration expense of \$161,799. This is recognised in a wholly owned subsidiary and accounted through intercompany transactions. The effect for the parent entity is to increase the Provision for diminution by \$161,799.

### 38. Explanation of transition to Australian equivalents to IFRSs (continued)

#### (c) Reclassification of grant income

Under AIFRS from 1 July 2004 the Group is required to recognise government grant income as other income, rather than revenue from continuing operations. The effect of this is:

#### (i) At 1 July 2004

No impact, since the reclassification in the income statement does not affect retained losses.

#### (d) Retained Earnings

The effect on retained earnings of the changes are set out above are as follows:

(ii) At 30 June 2005

No impact, since the reclassification in the income statement does not affect retained losses.

(iii) For the year ended 30 June 2005

For the Group there has been a increase in other income of \$1,409,844 and a corresponding decrease in revenue from continuing operations.

			Consolidated		Parent Entity
	Notes	1 July 2004 \$	<b>30 June 2005</b> \$	1 July 2004 \$	<b>30 June 2005</b> \$
Foreign currency translation reserve	38.4(a)	12,709	12,709		
Share-based payments reserve	38.4(b)	(56,816)	(218,615)	(56,816)	(218,615)
Total adjustment		(44,107)	(205,906)	(56,816)	(218,615)
Attributable to members of Starpharma Holdings Limited		(44,107)	(205,906)	(56,816)	(218,615)

#### 5. Financial instruments

The Group has no financial instruments that require restatement of comparatives for AASB 132 Financial Instruments: Disclosure and Presentation and AASB 139 Financial Instruments: Recognition and Measurement.

# Directors' Declaration

In the directors' opinion:

(a) the financial statements and notes set out on pages 41 to 77 are in accordance with the Corporations Act 2001, including:

- (i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and
- (ii) giving a true and fair view of the company's and consolidated entity's financial position as at 30 June 2006 and of their performance, as represented by the results of their operations, changes in equity and their cash flows, for the financial year ended on that date; and
- (b) there are reasonable grounds to believe that Starpharma Holdings Limited will be able to pay its debts as and when they become due and payable; and
- (c) the audited remuneration disclosures set out on pages 25 to 31 of the directors' report comply with Accounting Standards AASB 124 *Related Party Disclosures* and the *Corporations Regulations 2001*.

The directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the *Corporations Act 2001*.

This declaration is made in accordance with a resolution of the directors.

Peter T Bartels, AO Director Melbourne, 26th September 2006



PricewaterhouseCoopers ABN 52 780 433 757

Freshwater Place 2 Southbank Boulevard SOUTHBANK VIC 3006 GPO Box 1331L MELBOURNE VIC 3001 DX 77 Website:www.pwc.com/au Telephone 61 3 8603 1000 Facsimile 61 3 8603 1999

# Independent audit report to the members of Starpharma Holdings Limited

#### Matters relating to the electronic presentation of the audited financial report

This audit report relates to the financial report and remuneration disclosures of Starpharma Holdings Limited (the Company) and the Starpharma Holdings Group (defined below) for the financial year ended 30 June 2006 included on Starpharma Holdings Limited's web site. The Company's directors are responsible for the integrity of the Starpharma Holdings Limited web site. We have not been engaged to report on the integrity of this web site. The audit report refers only to the financial report and remuneration disclosures identified below. It does not provide an opinion on any other information which may have been hyperlinked to/from the financial report or the remuneration disclosures. If users of this report are concerned with the inherent risks arising from electronic data communications they are advised to refer to the hard copy of the audited financial report and remuneration disclosures to confirm the information included in the audited financial report and remuneration disclosures presented on this web site.

#### Audit opinion

In our opinion:

- 1. the financial report of Starpharma Holdings Limited:
  - gives a true and fair view, as required by the *Corporations Act 2001* in Australia, of the financial position of Starpharma Holdings Limited and the Starpharma Holdings Group (defined below) as at 30 June 2006, and of their performance for the year ended on that date, and
  - is presented in accordance with the *Corporations Act 2001*, Accounting Standards and other mandatory financial reporting requirements in Australia, and the *Corporations Regulations 2001*; and
- 2. the remunerations disclosures that are contained on pages 25 to 31 of the directors' report comply with Accounting Standard AASB 124 *Related Party Disclosures* (AASB 124) and the *Corporations Regulations* 2001.

This opinion must be read in conjunction with the rest of our audit report.

#### Scope

#### The financial report, remunerations disclosures and directors' responsibility

The financial report comprises the balance sheet, income statement, cash flow statements, statement of changes in equity, accompanying notes to the financial statements, and the directors' declaration for both Starpharma Holdings Limited (the company) and the Starpharma Holdings Group (the consolidated entity), for the year ended 30 June 2006. The consolidated entity comprises both the company and the entities it controlled during that year.

The company has disclosed information about the remuneration of directors and executives (remuneration disclosures) as required by AASB 124, under the heading "remuneration report" on pages 25 to 31 of the directors' report, as permitted by the *Corporations Regulations 2001*.

The directors of the company are responsible for the preparation and true and fair presentation of the financial report in accordance with the *Corporations Act 2001*. This includes responsibility for the maintenance of adequate accounting records and internal controls that are designed to prevent and detect fraud and error, and for the accounting policies and accounting estimates inherent in the financial report. The directors are also responsible for the remuneration disclosures contained in the directors' report.

#### Audit approach

We conducted an independent audit in order to express an opinion to the members of the company. Our audit was conducted in accordance with Australian Auditing Standards, in order to provide reasonable assurance as to whether the financial report is free of material misstatement and the remuneration disclosures comply with AASB 124 and the *Corporations Regulations 2001*. The nature of an audit is influenced by factors such as the use of professional judgement, selective testing, the inherent limitations of internal control, and the availability of persuasive rather than conclusive evidence. Therefore, an audit cannot guarantee that all material misstatements have been detected. For further explanation of an audit, visit our website <a href="http://www.pwc.com/au/financialstatementaudit">http://www.pwc.com/au/financialstatementaudit</a>.

We performed procedures to assess whether in all material respects the financial report presents fairly, in accordance with the *Corporations Act 2001*, Accounting Standards and other mandatory financial reporting requirements in Australia, a view which is consistent with our understanding of the company's and the consolidated entity's financial position, and of their performance as represented by the results of their operations, changes in equity and cash flows. We also performed procedures to assess whether the remuneration disclosures comply with AASB 124 and the *Corporations Regulations 2001*.

We formed our audit opinion on the basis of these procedures, which included:

- examining, on a test basis, information to provide evidence supporting the amounts and disclosures in the financial report and remuneration disclosures, and
- assessing the appropriateness of the accounting policies and disclosures used and the reasonableness of significant accounting estimates made by the directors.

Our procedures include reading the other information in the Annual Report to determine whether it contains any material inconsistencies with the financial report.

While we considered the effectiveness of management's internal controls over financial reporting when determining the nature and extent of our procedures, our audit was not designed to provide assurance on internal controls.

Our audit did not involve an analysis of the prudence of business decisions made by directors or management.

#### Independence

In conducting our audit, we followed applicable independence requirements of Australian professional ethical pronouncements and the *Corporations Act 2001*.

Pricuratu house Cogpers

PricewaterhouseCoopers

SC Bannatyne Partner

Melbourne 26 September 2006

# Shareholder information

The shareholder information set out below was applicable as at 14 September 2006

#### Supplementary information as required by Australian Stock Exchange listing requirements.

#### A. Distribution of equity shareholders

Analysis of numbers of equity security holders by size of holding as at 14 September 2006

		Class of equity security Ordinary shares
	Shares	Options
1–1,000	162	_
1,001–5,000	728	6
5,001–10,000	464	2
10,001–100,000	934	15
100,000 and over	162	7
	2,450	30

As at 14 September 2006 there were 169 holders of less than a marketable parcel of ordinary shares.

#### B. Equity security holders

Twenty largest security holders

Top 20 shareholders as at 14 September 2006:

		Ordinary shares
	Number held	Percentage of issued shares
1. ANZ Nominees Limited <cash a="" c="" income=""></cash>	17,690,522	11.97
2. National Nominees Ltd	11,210,619	7.59
3. Biomolecular Research Institute Limited	7,112,000	4.81
4. Peter Malcolm Colman	5,522,286	3.74
5. Arran Bay Pty Ltd	3,690,204	2.50
6. JPS Distribution Pty Ltd <raff a="" c="" family=""></raff>	3,567,831	2.41
7. Citicorp Nominees Pty Limited	3,416,267	2.31
8. Gilridge Pty Ltd	3,035,054	2.05
9. Biotech Capital Ltd	3,000,000	2.03
10. Queensland Investment Corporation	2,841,031	1.92
11. J P Morgan Nominees Australia Limited	2,791,200	1.89
12. Espasia Pty Ltd	2,788,700	1.89
13. Irrewarra Investments Pty Ltd <st a="" c=""></st>	2,320,000	1.57
14. Citicorp Nominees Limited <cfsil a="" boff="" c="" cwlth="" super=""></cfsil>	1,651,250	1.12
15. UBS Wealth Management Australia Nominees Pty Ltd	1,215,500	0.82
16. Kenneth Nominees Pty Ltd < Rayse Super Fund A/C>	1,200,000	0.81
17. Ag-Sun Technologies Pty Ltd	1,150,250	0.78
18. Irrewarra Investments Pty Ltd <cg2 a="" c=""></cg2>	1,129,196	0.76
19. Applecross Secretarial Services Pty Ltd <l a="" c="" family="" gorr=""></l>	1,077,000	0.73
20. Equity Trustees Limited < Australian New Horizons A/C>	1,031,812	0.70
	77,440,722	52.42

Unquoted equity securities

# Shareholder information (continued)

er on issue Number of holders
2.007.000 30
2,007,000

#### C. Substantial holders

The following information is extracted from the Company's register of substantial shareholders as at 14 September 2006:

	Number held	Percentage
Ordinary shares		
Acorn Capital Limited	10,303,608	9.26
Biomolecular Research Institute Limited	7,112,000	4.81
Starpharma Holdings Limited (voluntary escrow deed between the Company and Biomolecular Research Institute Limited)	7,112,000	4.81

#### D. Voting rights

The voting rights attached to each class of equity securities are set out below:

#### (a) Ordinary shares

On a show of hands every member present at a meeting in person or by proxy shall have one vote and on a poll each share shall have one vote.

(b) Options

No voting rights.

#### E. Securities subject to voluntary escrow

7,112,000 ordinary shares held by the Biomolecular Research Institute Limited are subject to a voluntary escrow deed which expires on 10 October 2006.

# Patent Report Current at 7 September 2006

# Summary of Patents & Patent Applications Assigned to Starpharma Pty Limited

Title:	Priority Date & PCT Number:	Country:	Number:	Status:
Granted Patents				
Antiviral Dendrimers	15 June 1994	Australia	682970	Granted
	PCT/AU 95/00350	Brazil	PI9508031.7	Granted
		Canada	2192446	Granted
		China	ZL95194145.3	Granted
		Europe	0765357	Granted
		Hong Kong	1002899	Granted
		Japan	2005-268847	Pending
		Mexico	231031	Granted
		New Zealand	287819	Granted
		Singapore	36429	Granted
		South Korea	0365028	Granted
		USA	6,190,650	Granted
Angiogenic Inhibitory Compounds	17 July 1996	Australia	715761	Granted
	PCT/AU 97/00447	Brazil	PI 9710375-6	Pending
		Canada	2262862	Granted
		China	ZL97196452.1	Granted
		Europe	0927217	Granted
		Japan	506372/98	Pending
		Mexico	990655	Pending
		New Zealand	333488	Granted
		Singapore	61126	Granted
		South Korea	0564714	Granted
		USA	6,426,067	Granted
Antiviral Linear Polymers	17 July 1996 PCT/AU 97/00446	Australia	730899	Granted
		Brazil	PI 9710376-4	Pending
		Canada	2262863	Pending
		China	ZL97196437.8	Granted
		Europe	97929037.6	Pending
		Japan	506371/98	Pending
		Mexico	231030	Granted
		New Zealand	333541	Granted
		Singapore	61123	Granted
		South Korea	0589022	Granted
		USA	6,740,635	Granted

# Patents & Patent Applications Assigned to Starpharma Pty Limited (continued)

Title:	Priority Date & PCT Number:	Country:	Number:	Status:
Antimicrobial & Antiparasitic Agents	14 Sept 1998 PCT/AU 99/00763	Australia	767970	Granted
		Brazil	PI9913712-7	Pending
		Canada	2343113	Pending
		China	99812270.X	Pending
		Europe	99945773.2	Pending
		Japan	569824/00	Pending
		Mexico	PAA/2001/002667	Pending
		New Zealand	510289	Granted
		Singapore	79613	Granted
		South Korea	10-2001-7003211	Pending
		USA	6,464,971	Granted
Inhibition of Toxic Materials	14 Sept 1998	Australia	767971	Granted
or Substances	PCT/AU 99/00762	Brazil	PI9913718-6	Pending
		Canada	2343205	Pending
		China	99812271.8	Pending
		Europe	99945772.4	Pending
		Japan	569823/00	Pending
		Mexico	PAA/2001/002665	Pending
		New Zealand	510376	Granted
		Singapore	79618	Granted
		South Korea	10-2001-7003255	Pending
		USA	09/786972	Pending
gents for the Prevention and	30 March 2001 PCT/AU 02/00407	Australia	2002245932	Pending
reatment of Sexually Transmitted Diseases – I		Brazil	PI0208411-2	Pending
1364365 - 1		Canada	2441357	Pending
		China	02807728.8	Pending
		Europe	02713925.2	Pending
		Hong Kong	04106895.9	Pending
		Japan	2002-578313	Pending
		Mexico	PA/a/2003/008909	Pending
		New Zealand	528230	Granted
		Singapore	99592	Granted
		South Korea	10-2003-7012867	Pending
		USA	10/472439	Pending

# Patents & Patent Applications Assigned to Starpharma Pty Limited (continued)

Title:	Priority Date & PCT Number:	Country:	Number:	Status:
Chemotherapeutic Agents	30 August 2001 PCT/AU 02/01180	Australia	2002325648	Pending
		Brazil	PI0212251-0	Pending
		Canada	2457676	Pending
		China	02816972.7	Pending
		Europe	02759901.8	Pending
		Japan	2003-523201	Pending
		Mexico	PA/a/2004/001583	Pending
		New Zealand	530759	Pending
		Singapore	102800	Granted
		South Korea	10-2004-7002770	Pending
		USA	10/487644	Pending
National Phase				
PCT/Complete Filed				
Delivery System	18 October 2005 PCT/AU2006/000120	PCT	PCT/AU2006/000120	Pending
		Argentina	060100368	Pending
		Chile	0212-2006	Pending
		Malaysia	PI20060435	Pending
		Taiwan	095103811	Pending
		Uruguay	29356	Pending
Inhibitory Compounds	21 Oct 2005 PCT/AU2006/000636	PCT	PCT/AU2006/000636	Pending
Modified Macromolecule	20 Jan 2006 PCT/AU2006/000637	PCT	PCT/AU2006/000637	PCT Filed
Provisional				
Polymer	25 Oct 2005	Provisional filed		
Dendrimer Polymers	1 Feb 2006	Provisional filed		
Composition	22 March 2006	Provisional filed		
Imaging Macromolecule	31 March 2006	Provisional filed		
Therapeutic Macromolecules	7 April 2006	Provisional filed		
Anti-viral Compounds	21 April 2006	Provisional filed		
Ligand Bearing Macromolecules	15 June 2006	Provisional filed		
Modified Macromolecule 2	11 August 2006	Provisional filed		
Modified Macromolecule 3	11 August 2006	Provisional filed		

# Corporate directory

Company Name	Starpharma Holdings Limited ABN 20 078 532 180	
Directors	P T Bartels AO – Chairman	
	J K Fairley – Chief Executive Officer	
	J W Raff – Deputy Chairman	
	P M Colman	
	R Dobinson	
	L Gorr	
	P J Jenkins	
Company Secretary	B P Rogers	
Registered office	Baker Building 75 Commercial Road, Melbourne, Victoria 3004	
Notice of Annual General Meeting	ng The annual general meeting of Starpharma Holdings Limited will be held at: Blake Dawson Waldron Level 39, 101 Collins Street, Melbourne Time: 4.00pm Date: Wednesday 15 November 2006	
Share Register	Computershare Investor Services 452 Johnston Street, Abbotsford VIC 3067 1300 850 505 (within Australia) +613 6415 4000 (outside Australia)	
Auditor	PricewaterhouseCoopers Freshwater Place Southbank VIC 3006 Australia	
Solicitors	Blake Dawson Waldron Level 39, 101 Collins Street, Melbourne VIC 3000 Australia	
Bankers	Commonwealth Bank of Australia,	
	National Australia Bank,	
	Wachovia Bank, USA	
Stock exchange listing	Australian Stock Exchange Limited (ASX) Level 3, 530 Collins Street, Melbourne, Vic 3000, Australia ASX Code: SPL	
	Starpharma's American Depositary Receipts (ADRs) trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to ten ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.	
Website address	www.starpharma.com	